

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
24 June 2004 (24.06.2004)

PCT

(10) International Publication Number
WO 2004/053054 A2

(51) International Patent Classification⁷: C12N
(21) International Application Number: PCT/IL2003/001040
(22) International Filing Date: 9 December 2003 (09.12.2003)
(25) Filing Language: English
(26) Publication Language: English
(30) Priority Data:
60/431,728 9 December 2002 (09.12.2002) US
(71) Applicant (*for all designated States except US*): NATS-
PEARS LTD. [IL/IL]; 2a Katzir Street, Ramat Gan 52656
(IL).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and
(75) Inventors/Applicants (*for US only*): MANDELBOIM, Ofer [IL/IL]; 58 Hayarden Street, 73142 Shoam (IL).
PORGADOR, Angel [IL/IL]; 11 Tavlan Street, Lehavim 85338 (IL).
(74) Agent: WEBB, Cynthia; Webb & Associates, P.O. Box 2189, Rehovot 76121 (IL).

Published:

— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NK CELL RECEPTOR CONJUGATES FOR TREATING MALIGNANCIES

(57) Abstract: The present invention relates generally to compositions useful in therapies involving the selective destruction of tumor cells in vivo. In particular, this invention relates to a conjugate which comprises a target recognition segment and an active cytotoxic segment. The target recognition segment comprises a receptor specific to NK cells, wherein the receptor binds to a cellular ligand expressed on the surface of a tumor cell, and the active segment comprises an agent capable of exerting a cytotoxic effect on the tumor cell. The target recognition segment derived from the natural killer receptor NKp30 has been found to be particularly effective in vivo.

WO 2004/053054 A2

NK CELL RECEPTOR CONJUGATES FOR TREATING MALIGNANCIES

FIELD OF THE INVENTION

The present invention relates generally to compositions useful in the treatment
5 of various cancers and to therapies involving the selective destruction of tumor cells in
vivo. More specifically, the present invention relates to conjugates and fusion proteins of
Natural Killer cytotoxicity receptors NKp30, NKp46 and NKp44, or active fragments
thereof and an active agent selected from a cytotoxic drug or an Ig fragment effective in
targeting tumor cells in vivo. Particularly preferred compositions are conjugates and
10 fusion proteins of the NK cell specific receptor NKp30 with the Fc fragment of an Ig
molecule.

BACKGROUND OF THE INVENTION

A key to the development of successful antitumor agents is the ability to design
15 agents that will kill tumor cells selectively, while exerting relatively little, if any,
untoward effects against normal tissues. This goal has been elusive to achieve, in that
there are few qualitative differences between neoplastic and normal tissues. Because of
this, much research over the years has focused on identifying tumor-specific antigens that
can serve as immunological targets both for chemotherapy and diagnosis. Many tumor-
20 specific, or quasi-tumor-specific ("tumor-associated"), markers have been identified as
tumor cell antigens that can be recognized by specific antibodies. Unfortunately, it is
generally the case that tumor-specific antibodies of themselves will not exert sufficient
antitumor effects to make them useful in cancer therapy.

25 Natural Killer (NK) cells destroy virus-infected and transformed cells apparently
without prior antigen stimulation (1, 2). The interaction between NK cells and their
targets is mediated via a complex array of NK inhibitory and activating receptors (3-7).
Heavily implicated in this interplay are inhibitory receptors of the NK cell surface, the
ligands of which are polymorphic and non-polymorphic major histocompatibility
30 complex (MHC) class I molecules (3-7). With regard to activation, some NK cells
express activation receptors specific for MHC class I molecules homologous to various
NK inhibitory receptors (3-7).

Three novel lysis receptors, expressed mainly on human NK cells, were recently identified. These natural cytotoxicity receptors (NCR) include the NKp30, NKp44, and NKp46 molecules (3, 5). All of these NCR are capable of mediating direct killing of tumor and virus-infected cells and are specific for non-MHC ligands. NKp46 and NKp30
5 are present exclusively on NK cells, whether resting or activated, while NKp44 is expressed specifically by activated NK cells (3, 5).

The most distinctive role of the NCRs in NK cells activity has been attributed to their involvement in recognition and killing of tumor cells. This has become evident by
10 the ability of anti-NCR monoclonal antibodies to block NK-mediated killing of most tumor lines (8-11) and by the strict correlation that exists between the density of NCRs expression on NK cells and their ability to kill tumor targets (11). More recently, the importance of NCRs in vivo was illustrated in acute myeloid leukemia (AML) patients expressing insufficient amount of either NCR or NCR ligands, thereby rendering the
15 leukemia cells resistant to NK cytotoxicity (12).

International Patent Application WO 02/08287 of the present inventors discloses NK receptor fusion proteins in which the extracellular portion of the various NK receptors is conjugated to an active segment selected from an immunoglobulin (Ig) or Ig
20 fragment, a cytotoxic moiety or an imaging moiety. WO 02/08287 further discloses that the NK receptor fusion proteins exhibit specific interactions with tumor cells and viral-infected cells, and these fusion proteins are disclosed as useful for therapeutic applications ex vivo, as well as in vivo. WO 02/08287 generally discloses fusion proteins comprising any one of the three NK cytotoxicity receptors, namely NKp46, NKp44 and
25 NKp30. Specific fusion proteins are disclosed and claimed only for NKp46 and NKp44. The teachings of WO 02/08287 are incorporated herein as if set forth herein in their entirety. It is to be understood explicitly that the present invention excludes any of the specific compositions claimed in WO 02/08287.

30 WO 01/36630 discloses NKp30, and the use of NKp30 for detecting NK cells and for selective removal of NK cells from a sample. WO 01/36630 further discloses the use of NKp30 antiserum for in vitro stimulation of NK cells cytotoxicity. WO 01/36630 neither discloses nor teaches any therapeutic utility of NKp30 against malignant diseases

or even specific targeting of a tumor cell *in vivo* using either NKp30 or NKp30 fusion proteins.

There exists a long-felt need for anti-tumor agents that will be selective for tumor cells, while exerting relatively little, if any, untoward effects against normal tissues.

SUMMARY OF THE INVENTION

It is an object of the present invention to provide compositions and methods for inhibiting or reducing the growth of a tumor in a patient. It is a further object of the present invention to provide compositions and therapeutic methods for selectively lysing tumor cells or for selectively delivering a cytotoxic drug to a target tumor cell in a patient for the purpose of eliminating the target tumor cell either directly or by creating an environment lethal to the target cell.

The present invention relates generally to Natural Killer Cytotoxicity receptor (NCR) conjugates and fusion proteins that are effective in targeting tumor cells *in vivo*. The present invention further relates to NCR conjugates and fusion proteins that are effective in inhibiting the growth of the tumor or reducing the size of the tumor.

The NCR conjugates or fusion proteins according to the present invention comprise a first segment comprising an NCR selected from the group consisting of: NKp46, NKp44 and NKp30, or active fragments thereof, and a second segment comprising an agent active in inducing cytotoxicity. The conjugates or fusion proteins according to the invention comprise an active segment selected from a cytotoxic substance, an Immunoglobulin (Ig) molecule or an active fragment of an Ig molecule such as the Fc fragment of Ig. It is to be understood explicitly that the present invention discloses and claims certain novel conjugates and fusion proteins, particularly those comprising NKp30 or active fragments thereof.

Unexpectedly, it is now disclosed that of the various NK conjugates and fusion proteins tested, those comprising the natural killer cytotoxicity receptor NKp30 or active fragments thereof were found to be especially effective in inhibiting the growth of tumors *in vivo*. As exemplified herein below by way of a non-limiting example, NKp30 conjugates according to the present invention were particularly effective in inhibiting

growth of PC3 prostate tumor cells *in vivo* as compared to NKp46 and NKp44 conjugates.

5 According to one aspect, the present invention provides a polypeptide conjugate and pharmaceutical compositions comprising same, wherein the polypeptide conjugate comprises as a first segment an NCR or fragments thereof and as a second segment an agent active in inducing cytotoxicity.

10 According to one embodiment, the present invention provides a polypeptide conjugate comprising a first segment selected from the group consisting of: NKp30, NKp44, NKp46 or a functional fragments thereof; and a second segment selected from the group consisting of: an Ig molecule, a fragment of an Ig molecule and an Fc portion of an Ig molecule.

15 According to a preferred embodiment, the polypeptide conjugate comprises NKp30 or a functional fragment thereof and an Fc portion of an Ig molecule.

According to a currently preferred embodiment, the polypeptide conjugate comprises the amino acid sequence set forth herein as SEQ ID NO:4.

20

According to yet another embodiment, the present invention provides a pharmaceutical composition comprising as an active ingredient a conjugate capable of eliminating a tumor or inhibiting the growth of the tumor in a subject, and a pharmaceutically acceptable carrier, the conjugate comprising:

- 25 (a) a target recognition segment comprising an NCR or an active fragment thereof, the NCR selected from the group consisting of: NKp30, NKp46, and NKp44, or a functional fragment thereof, wherein the NCR binds to a cellular ligand expressed on the surface of a target tumor cell;
- (b) an active segment comprising a cytotoxic agent that promotes the lysis of the target tumor cell; and
- 30 (c) a pharmaceutically acceptable carrier or diluent.

According to one preferred embodiment of the invention the pharmaceutical composition comprises as an active ingredient a polypeptide conjugate comprising NKp30 or a functional fragment thereof and an Fc portion of an Ig molecule.

5 According to a currently preferred embodiment, the pharmaceutical composition comprises as an active ingredient a polypeptide conjugate having the sequence set forth herein as SEQ ID NO:4.

10 According to another aspect, the present invention provides isolated polynucleotides encoding the polypeptide conjugates of the present invention, constructs comprising the polynucleotides, vectors comprising these constructs, hosts cells harboring these vectors, and means of producing the polypeptides from cultures of these host cells.

15 According to one embodiment, the present invention provides an isolated polynucleotide sequence encoding the polypeptide conjugate of the invention.

20 According to another embodiment, the isolated polynucleotide encodes a polypeptide conjugate comprising NKp30 or a functional fragment thereof and an Fc portion of an Ig molecule.

According to one preferred embodiment, the polynucleotide encodes a polypeptide having the sequence set forth herein as SEQ ID NO:4.

25 According to a currently preferred embodiment, the polynucleotide comprises the sequence set forth herein as SEQ ID NO:11, or a functional fragment thereof.

30 According to yet another embodiment, the present invention provides a vector comprising a polynucleotide encoding a polypeptide conjugate comprising NKp30 or a functional fragment thereof and an Fc portion of an Ig molecule.

According to yet another embodiment, the vector is a plasmid or a virus. According to yet another embodiment, the vector is a virus selected from the group consisting of: adenoviruses, retroviruses and lentiviruses.

According to yet another embodiment, the vector further comprises at least one regulatory element operably linked to the polypeptide conjugate of the invention, the at least one regulatory element is selected from the group consisting of: promoter, initiation codon, stop codon, polyadenylation signal, enhancer and selection marker.

5

According to one embodiment, the present invention provides a host cell comprising the vector of the invention. According to another embodiment the host cell is eukaryotic or prokaryotic. According to yet another embodiment, the present invention provides a host cell capable of expressing the polypeptide conjugate of the invention.

10

According to yet another aspect, the present invention provides a method for treating a malignant disease in a subject comprising administering to the subject a pharmaceutically effective amount of a polypeptide conjugate comprising:

15

a) a target recognition segment comprising a Natural Killer cytotoxic receptor (NCR) or an active fragment thereof, wherein the NCR is selected from the group consisting of: NKp46, NKp44, NKp30 or a functional fragment thereof, that binds to a cellular ligand expressed on the surface of a target tumor cell; and

20

b) an active segment comprising an active agent, the active agent being capable of exerting a cytotoxic effect on said target cell,

the conjugate being capable of eliminating or inhibiting the growth of the tumor cells associated with the disease, thereby treating the disease.

25

According to a currently preferred embodiment of the invention the polypeptide conjugate used in this method comprises NKp30 and an Fc portion of an Ig molecule having the sequence set forth herein as SEQ ID NO:4.

30

According to yet another aspect, the present invention provides a method of inhibiting the growth of a tumor in a subject comprising administering to the subject an effective amount of a polypeptide conjugate comprising:

a) a target recognition segment comprising an NCR or an active fragment thereof, wherein said NCR is selected from the group consisting of: NKp46, NKp44, NKp30 or a functional fragment thereof, wherein the target recognition segment is

capable of binding to a cellular ligand expressed on the surface of a target tumor cell,; and

- b) an active segment comprising an active agent that promotes the lysis of the target tumor cell, thereby inhibiting the growth of the tumor in said subject.

5

According to a currently preferred embodiment of the invention the polypeptide conjugate used in this method comprises NKp30 and an Fc portion of an Ig molecule having the sequence set forth herein as SEQ ID NO:4.

10

It is noted that in certain cases, the conjugates of the present invention are capable of eliminating the tumor to the extent that there is no gross evidence for the presence of a tumor in the subject. In other cases, the conjugates of the present invention are capable of reducing the size of the tumor significantly. Preferably the conjugates are capable of reducing the size of a solid tumor by 50% of the initial size, more preferably to 30% of the initial size, most preferably to 10% of the initial size. The size of the tumor in the subject may be determined by any of the diagnostic or imaging techniques as are well known in the art, including for example by Computed Tomography Imaging (CT) or Magnetic Resonance Imaging (MRI).

15

20

The NCR conjugates according to the present invention comprise an NCR selected from the group consisting of: NKp30, NKp46 and NKp44, or active fragments thereof. The conjugates according to the invention further comprise an active segment that is selected from a cytotoxic substance, an Immunoglobulin (Ig) molecule or an active fragment of the Ig including but not limited to the Fc fragment of Ig.

25

According to one exemplary embodiment, the NCR conjugate comprises NKp46 covalently attached to the Fc portion of an Ig molecule, the amino acid sequence of which is denoted as SEQ ID NO:1 and the nucleotide sequence of which is denoted as SEQ ID NO:8. In a preferred embodiment, the NCR conjugate comprises the domain 2 (D2 domain) of NKp46 covalently attached to the Fc molecule, the amino acid sequence of which is denoted as SEQ ID NO:3 and the nucleotide sequence of which is denoted as SEQ ID NO:10. It is noted that while both Isoform A and Isoform B of NKp46 may be used in the conjugates of the invention, the A Isoform is preferred.

30

According to one currently more preferred embodiment, the NCR conjugate comprises NKp30 covalently attached to the Fc portion of an Ig molecule, the amino acid sequence of which is set forth herein as SEQ ID NO:4 and the nucleotide sequence of which is set forth herein as SEQ ID NO:11. This NKp30-Fc conjugate was unexpectedly discovered to be very effective in inhibiting the growth of a tumor in vivo. It is to be understood explicitly that any analog, derivative or other conjugate having the same attributes is encompassed within the scope of the present invention.

According to yet another embodiment, the NCR conjugate comprises NKp44 covalently attached to Fc molecule, the amino acid sequence of which is denoted as SEQ ID NO:5 and the nucleotide sequence of which is denoted as SEQ ID NO:12.

According to yet another embodiment, the NCR conjugate comprises the NK44-DS fragment covalently attached to Fc molecule, the amino acid sequence of which is denoted as SEQ ID NO:6 and the nucleotide sequence of which is denoted as SEQ ID NO:13. In yet another embodiment, the NCR conjugate comprises the NK44-DL fragment covalently attached to Fc molecule, the amino acid sequence of which is denoted as SEQ ID NO:7 and the nucleotide sequence of which is denoted as SEQ ID NO:14.

20

As noted above, certain preferred conjugates according to the present invention comprise the Fc fragment of an immunoglobulin molecule as the active segment. The Fc conjugates to the natural killer cytotoxicity receptors is therapeutically useful irrespective of any specific mechanism of action. Without wishing to be bound by any theory, the binding of the Fc-containing conjugates to the target tumor cell can potentially induce cell lysis via three possible mechanisms:

- 1) Cellular Cytotoxicity - Several different leukocytes including neutrophils, eosinophils, macrophages and NK cells contain Fc receptors and are capable of binding to conjugate-bound tumor cells via the Fc segment, resulting in the lysis of the tumor cells.
- 2) Complement-Dependent Cytotoxicity- The lysis of the conjugate-bound target tumor cells may be mediated by activation of the complement pathway.

30

3) Induction of programmed cell death (Apoptosis) following the binding of the Fc-containing conjugates to the target tumor cells and activation of apoptosis intracellular signaling pathways leading to cell death.

5 According to yet another aspect, the present invention provides a method of delivering a cytotoxic substance to a target tumor cell in a subject in need thereof comprising:

b. administering to the subject a therapeutically effective amount of a conjugate comprising a first segment being a target recognition segment comprising an NCR or an
10 active fragment thereof, the NCR selected from the group consisting of NKp46, NKp44, NKp30 or a functional fragment thereof, and a second segment comprising a cytotoxic agent, the target recognition segment capable of binding to a cellular ligand expressed on the surface of said target tumor cell, wherein the binding of the conjugate to the cellular ligand promotes the internalization of said conjugate into said target tumor cell, thereby
15 delivering said cytotoxic agent to said target tumor cell.

According to one preferred embodiment, the conjugate for delivering a cytotoxic substance to a target tumor cell in a subject comprises NKp30 or an active fragment thereof. According to additional preferred embodiments, the conjugate for
20 delivering a cytotoxic substance to a target tumor cell in a subject comprises NKp46 or domain 2 of NKp46 covalently linked to a cytotoxic substance. The advantage of the conjugates of the present invention is that the binding of the conjugate to the cellular ligand promotes the internalization of said conjugate within said target tumor cell. Thus, it is preferred that the conjugates comprise a cytotoxic agent which promotes cell death
25 upon internalization of the cytotoxic agent into the cell. Preferred cytotoxic agents include, but are not limited to, radioisotopes, steroids, chemotherapeutic drugs, and antisense oligonucleotides.

According to one embodiment, the chemotherapeutic agents are selected from
30 the group consisting of: a hormone such as a steroid; an antimetabolite such as cytosine arabinoside, fluorouracil, methotrexate or aminopterin; an anthracycline; mitomycin C; a vinca alkaloid; demecolcine; etoposide; mithramycin; an antitumor alkylating agent such as chlorambucil. Other drugs such as busulfan, carmustine, cisplatin, cyclophosphamide,

doxorubicin, ifosfamide, nitrogen mustards, nitrosureas, melphalan or antitumor antibiotics such as bleomycin or daunorubicin may be used..

According to another embodiment, the radioisotope agents for therapeutic use
5 may be for example: iodine¹³¹, iodine¹²³, technecium^{99m}, indium¹¹¹, rhenium¹⁸⁸,
rhenium¹⁸⁶, gallium⁶⁷, copper⁶⁷, yttrium⁹⁰, iodine¹²⁵ or astatine²¹¹.

According to another embodiment, the cytotoxic substance may be a cytotoxin
such as a plant-, fungus- or bacteria-derived toxin. For example, a ribosome inactivating
10 protein, α -sarcin, aspergillin, restrictocin, a ribonuclease, diphtheria toxin or
pseudomonas exotoxin may be used as a cytotoxic substance.

It is proposed that the various methods and compositions of the present
invention will be broadly applicable to the treatment of any tumor, including solid and
15 non-solid tumors. If the neoplastic tissue is a part of the lymphatic or immune systems,
the non-solid tumors may include circulating malignant cells. Malignancies of other
tissues or organs may produce solid tumors. In one preferred example, the conjugates
according to the present invention are useful in the treatment of a neoplastic disease
associated with solid tumors including but not limited to prostate cancer, melanoma,
20 colon cancer, breast cancer, pancreatic cancer, ovarian cancer, osteosarcoma and renal
cell carcinoma.

These and further embodiments will be apparent from the detailed description and
examples that follow.

25

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 demonstrates the binding of NKp46, NKp44, or NKp30 conjugates to various
cancer cells but not to normal peripheral blood lymphocytes (PBL).

30

Figure 2 demonstrates the binding of the NKp46-D1-Ig and NKp46-D2-Ig conjugates to
melanoma cell lines and prostate cancer cell lines.

Figure 3 demonstrates the killing of human prostate cancer cells by NKp30-Ig and NKp46D2-Ig.

Figure 4 demonstrates NKp30-Ig-mediated tumor regression in nude mice.

5

Figure 5 illustrates the complete or partial response obtained by the NKp30-Ig conjugate as revealed by the size of the tumor.

Figure 6 demonstrates that NKp46D2-Ig conjugate binds to the cell surface of 1106mel cells and then internalized to the intracellular domain.

10

Figure 7 demonstrates a strong binding of NKp46D2-Ig and NKp30-Ig to a tissue section derived from adenomacarcinoma but not to a tissue section derived from benign prostatic hyperplasia (BPH).

15

Figure 8 demonstrates that NKp30-Ig and NKp46D2-Ig bind to a tissue section derived from malignant melanoma but not to a tissue section derived from benign nevus tissue.

Figure 9 demonstrates that NKp46D2-Ig specifically binds to a tissue section derived from pancreatic cancer.

20

DETAILED DESCRIPTION OF THE INVENTION

In order that this invention may be better understood, the following terms and definitions are herein provided.

25

The term "specific binding" as used herein refers to the preferential association of a molecule with a cell or tissue bearing a particular target molecule or marker and not to cells or tissues lacking that target molecule or expressing that target molecule at low levels. It is, of course, recognized that a certain degree of non-specific interaction may occur between a molecule and a non-target cell or tissue.

30

The term "conjugate" refers to a polypeptide formed by the joining of two or more polypeptides through a peptide bond formed between the amino terminus of one polypeptide and the carboxyl terminus of another polypeptide. The conjugate may be

formed by the chemical coupling of the constituent polypeptides or it may be expressed as a single polypeptide fusion protein from a nucleic acid sequence encoding the single contiguous conjugate. In those instances where the active segment of the conjugate is a cytotoxic agent that is not a polypeptide it is to be understood that the cytotoxic agent is attached via chemical coupling to the polypeptide.

The term "cellular ligand" refers generally to tumor cell membrane molecules capable of reacting with the target recognition segment of the conjugate of the invention.

The term "target recognition segment" refers to a targeting segment capable of specifically recognizing and binding to a target tumor cell via its cellular ligand.

The term "delivering a cytotoxic substance to a target tumor cell" means that the amount of substance associated with a target tumor cell is at least two-fold, preferably 5-fold, more preferably 10-fold higher than the amount of the substance associated with a normal cell.

The term "target cells" refers to cells that are killed by the cytotoxic activity of the conjugate of the invention. The target cells express the ligand for at least one of NKp46, NKp44 and NKp30 molecules and include, in particular, cells that are malignant or otherwise derived from solid as well as non-solid tumors.

The terms "NKp30, NKp44, and NKp46" refer to natural cytotoxicity receptors expressed on human NK cells which are capable of mediating direct killing of tumor and virus-infected cells.

The term "active fragments" refers to "fragments", "variants", "analogs" or "derivatives" of the molecule. A "fragment" of a molecule, such as any of the nucleic acid or the amino acid sequence of the present invention is meant to refer to any nucleotide or amino acid subset of the molecule. A "variant" of such molecule is meant to refer to a naturally occurring molecule substantially similar to either the entire molecule or a fragment thereof. An "analog" of a molecule is a homologous molecule from the same species or from different species. The amino acid sequence of an analog or derivative may differ from the specific molecule, e.g. the NKp46, NKp30 or NKp44

molecule, used in the present invention when at least one residue is deleted, inserted or substituted.

5 The term "cytotoxic effect" refers to a killing of target cells by any of a variety of biological, biochemical, or biophysical mechanisms. Cytolysis refers more specifically to activity in which the effector lyses the plasma membrane of the target cell, thereby destroying its physical integrity. This results in the killing of the target cell.

10 The term "complement-mediated lysis" refers to the process by which the complement-dependent coagulation cascade is activated, multi-component complexes are assembled, ultimately generating a lytic complex that has direct lytic action, causing cell permeabilization.

15 The term "cell-mediated cytotoxicity or destruction" refers to antibody-dependent, cell-mediated cytotoxicity (ADCC) and natural killer (NK) cell killing.

The present invention provides a method for treating a subject having a tumor using an NCR conjugate for specific targeting of tumor cells in vivo. The NCR conjugate of the invention comprises a target recognition segment and an active segment. The target
20 recognition segment comprises a receptor specific to NK cells or a fragment thereof, wherein the receptor binds to a cellular ligand expressed on the surface of a tumor cell, and the active segment comprises an active substance, said active substance is capable of exerting a cytotoxic effect on the tumor cell.

25 The method of the invention relates to a specific elimination of tumor cells in vivo, and comprises administering to a subject at least one dose of a pharmaceutically effective amount of the NCR conjugate of the invention. The "pharmaceutically effective amount" is an amount of the NCR conjugate effective to specifically kill at least a portion, and preferably a significant portion, of the tumor cells, upon binding of the NCR
30 conjugate to a cellular ligand expressed on the surface of said tumor cells.

In one embodiment, the NCR conjugate comprises NKp46 covalently attached to Fc molecule, the amino acid sequence of which is denoted as SEQ ID NO:1 and the nucleotide sequence of which is denoted as SEQ ID NO:8. In a preferred embodiment,

the NCR conjugate comprises the domain 2 (D2 domain) of NKp46 covalently attached to the Fc molecule, the amino acid sequence of which is denoted as SEQ ID NO:3 and the nucleotide sequence of which is denoted as SEQ ID NO:10. It is noted that while both Isoform A and Isoform B of NKp46 may be used in the conjugates of the invention, the A Isoform is preferred.

In more preferred embodiment, the NCR conjugate comprises NKp30 covalently attached to Fc molecule, the amino acid sequence of which is denoted as SEQ ID NO:4 and the nucleotide sequence of which is denoted as SEQ ID NO:11. The NKp30-Fc conjugate was unexpectedly discovered to be very effective in inhibiting the growth of a tumor in vivo.

In yet another embodiment, the NCR conjugate comprises NKp44 covalently attached to Fc molecule, the amino acid sequence of which is denoted as SEQ ID NO:5 and the nucleotide sequence of which is denoted as SEQ ID NO:12. In yet another embodiment, the NCR conjugate comprises the NK44-DS fragment covalently attached to Fc molecule, the amino acid sequence of which is denoted as SEQ ID NO:6 and the nucleotide sequence of which is denoted as SEQ ID NO:13. In yet another embodiment, the NCR conjugate comprises the NK44-DL fragment covalently attached to Fc molecule, the amino acid sequence of which is denoted as SEQ ID NO:7 and the nucleotide sequence of which is denoted as SEQ ID NO:14.

A further aspect the invention relates to a pharmaceutical composition comprising as an active ingredient a conjugate comprising:

- a target recognition segment comprising an NCR or an active fragment thereof, the NCR selected from the group consisting of: NKp46, NKp44, NKp30 or a functional fragment thereof that binds to a cellular ligand expressed on the surface of a target tumor cell; and
- an active segment comprising an active agent that promotes the lysis of the target tumor cell;
- and a pharmaceutically acceptable carrier, stabilizer or diluent.

The active segment of the composition of the invention may be an Ig fragment, preferably the Fc portion of an Ig molecule. Alternatively, the active segment may be a

cytotoxic substance, such as a chemotherapeutic agent, a radiotherapeutic agent or a cytotoxin capable of exerting a cytotoxic effect on the tumor cell.

5 In preferred embodiments, the method of the invention includes administering to a subject in need a pharmaceutical composition comprising an amount of NCR-Ig conjugate effective to induce specific cytotoxicity in tumor cells or other diseased cells.

10 Without wishing to be bound by any particular theory or mechanism of action, according to one embodiment the cytotoxicity may be Antigen-Dependent Cellular Cytotoxicity (ADCC). Specifically, the NCR-Ig conjugates can induce the activation of immune cells that are equipped with Fc or complement receptors, such as macrophages and NK cells. These cells are capable of binding to the NCR-Ig conjugate-coated tumor cells and eliminate them via phagocytosis or via cell-mediated cytotoxicity.

15 According to an alternative embodiment, the NCR-Ig conjugates of the present invention may also activate the complement-mediated lysis of at least a portion of the tumor cells. The complement system is activated principally by the binding of the first classical pathway component, C1, to the Fc portion of antigen-complexed antibody molecules. Therefore, the conjugates comprising NKp30, NKp46 or NKp44, and the Fc
20 portion of an Ig molecule, can serve as target for the complement system *in vivo*.

In another embodiment, the method of the invention employs a conjugate wherein the NCR is covalently attached to a cytotoxic substance. According to the principles the conjugates of the invention encompass the use of any cytotoxic substance
25 or agent that can be conjugated to the target recognition segment of an NCR, and can be thus targeted or delivered in active form to the target cell. In any event, it is proposed that cytotoxic agents may be successfully conjugated to the targeting segment in a manner that will allow their targeting, internalization, release or presentation to the target cells as required. Conjugation may be accomplished using any known conjugation technologies
30 as are well known in the art [for example, Ghose, *et al.*, Critical Reviews in Therapeutic Drug Carrier Systems, 3:256-359 (1987)].

It is to be appreciated that the targeting segment of the conjugate of the invention may be linked to the active segment, either directly or indirectly by conjugating or coupling these segments to any one of lipid backbone or carbohydrate backbone.

5 Exemplary cytotoxic substances include chemotherapeutic agents, radioisotopes as well as cytotoxins. In one embodiment, the chemotherapeutic agents are selected from the group consisting of: a hormone such as a steroid; an antimetabolite such as cytosine arabinoside, fluorouracil, methotrexate or aminopterin; an anthracycline; mitomycin C; a vinca alkaloid; demecolcine; etoposide; mithramycin; an antitumor
10 alkylating agent such as chlorambucil. Other drugs such as busulfan, carmustine, cisplatin, cyclophosphamide, doxorubicin, ifosfamide, nitrogen mustards, nitrosureas, melphalan or antitumor antibiotics such as bleomycin or daunorubicin may be used..

In another embodiment, the radioisotope agents for therapeutic use may be for
15 example: iodine¹³¹, iodine¹²³, technecium^{99m}, indium¹¹¹, rhenium¹⁸⁸, rhenium¹⁸⁶, gallium⁶⁷, copper⁶⁷, yttrium⁹⁰, iodine¹²⁵ or astatine²¹¹.

In another embodiment, the cytotoxic substance may be a cytotoxin such as a plant-, fungus- or bacteria-derived toxin. For example, a ribosome inactivating protein, α -sarcin, aspergillin, restrictocin, a ribonuclease, diphtheria toxin or pseudomonas exotoxin
20 may be used as a cytotoxic substance.

Particularly preferred cytotoxins include Pseudomonas exotoxins, Diphtheria toxins, ricin, abrin, cytotoxic prodrugs, ribonucleases (e.g., Ribonuclease A), and
25 ribozymes. Pseudomonas exotoxin and Diphtheria toxin, doxorubicin and maytansinoids are most preferred. Pseudomonas exotoxin A (PE) is an extremely active monomeric protein (molecular weight 66 kD), secreted by Pseudomonas aeruginosa, which inhibits protein synthesis in eukaryotic cells. Like PE, diphtheria toxin (DT) kills cells by ADP-ribosylating elongation factor 2 thereby inhibiting protein synthesis.

30

In another embodiment, the cytotoxic moiety is a cytotoxic prodrug. The conjugate molecule bearing the prodrug is contacted with the target tumor cell thereby localizing the prodrug at the tumor site. The prodrug is then contacted with its corresponding conversion enzyme thereby converting the prodrug into its cytotoxic form

at the tumor site thereby causing the inhibition of growth or killing of tumor cells. Suitable prodrugs are well known to those of skill in the art and include, for example, etoposide-4' phosphate or 7-(2' aminoethyl phosphate)mitomycin which are activated in the presence of alkaline phosphatase (AP) to effect killing of tumor cells. Other prodrugs
5 include the prodrug N-(p-hydroxyphenoxyacetyl)adriamycin which is used in conjunction with penicillin V amidase (PVA) or 5-fluorocytosine which is used in conjunction with cytosine deaminase (CD) (see, e.g., U.S. Pat. No. 4,957,278).

Ricin and abrin are plant derived cytotoxins well known to those of skill in the
10 art. Like Pseudomonas exotoxin and Diphtheria toxin, ricin and abrin can also be linked to a targeting moiety for specific delivery to cell bearing a particular target molecule. Means of joining ricin and abrin to a targeting molecule are well known to those of skill in the art (see, e.g., Pastan et al. Ann. Rev. Biochem., 61: 331-354 (1992), Thrush et al., Ann. Rev. Imm. 14: 49-71 (1996) and references cited therein).

15 In another embodiment, the cytotoxic moiety may be an antisense oligonucleotide molecule capable of hybridizing to specific ribonucleotide sequence within the cell, thereby inhibiting the expression of the protein encoded by this ribonucleotide sequence. Antisense oligonucleotides have been safely and effectively
20 administered to humans for inhibiting the expression of specific proteins in the cell. It is thus established that oligonucleotides can be useful therapeutic modalities that can be configured to be useful in treatment regimes for treatment of cells, tissues and animals, especially humans. In the context of this invention, the term "oligonucleotide" refers to an oligomer or polymer of ribonucleic acid (RNA) or deoxyribonucleic acid (DNA) or
25 mimetics thereof. This term includes oligonucleotides composed of naturally-occurring nucleobases, sugars and covalent internucleoside (backbone) linkages as well as oligonucleotides having non-naturally-occurring portions which function similarly. Such modified or substituted oligonucleotides are often preferred over native forms because of desirable properties such as, for example, enhanced cellular uptake, enhanced affinity for
30 nucleic acid target and increased stability in the presence of nucleases.

It is proposed that the various methods and compositions of the invention will be broadly applicable to the treatment of any tumor, including solid and non-solid tumors. If the tissue is a part of the lymphatic or immune systems, malignant cells may include

non-solid tumors of circulating cells. Malignancies of other tissues or organs may produce solid tumors. Exemplary solid tumors to which the present invention is directed include but are not limited to carcinomas of the lung, breast, ovary, stomach, pancreas, larynx, esophagus, testes, liver, parotid, biliary tract, colon, rectum, cervix, uterus, endometrium, kidney, bladder, prostate, thyroid, squamous cell carcinomas, adenocarcinomas, small cell carcinomas, melanomas, gliomas, neuroblastomas, and the like. Exemplary non-solid tumors to which the present invention is directed include but are not limited to B cell Lymphoma, T cell Lymphoma, or Leukemia such as Chronic Myelogenous Leukemia.

In a preferred embodiment, the conjugates of the present invention are synthesized using recombinant DNA methodology. Generally this involves creating a DNA sequence that encodes the conjugate, placing the DNA in an expression cassette under the control of a particular promoter, expressing the protein in a host, isolating the expressed protein and, if required, renaturing the protein.

DNA encoding the conjugates of this invention may be prepared by any suitable method, including, for example, cloning and restriction of appropriate sequences or direct chemical synthesis by methods such as the phosphotriester method of Narang et al. *Meth. Enzymol.* 68: 90-99 (1979); the phosphodiester method of Brown et al., *Meth. Enzymol.* 68: 109-151 (1979); the diethylphosphoramidite method of Beaucage et al., *Tetra. Lett.*, 22: 1859-1862 (1981); and the solid support method of U.S. Pat. No. 4,458,066.

Chemical synthesis produces a single stranded oligonucleotide. This may be converted into double stranded DNA by hybridization with a complementary sequence, or by polymerization with a DNA polymerase using the single strand as a template. One of skill would recognize that while chemical synthesis of DNA is limited to sequences of about 100 bases, longer sequences may be obtained by the ligation of shorter sequences. Alternatively, subsequences may be cloned and the appropriate subsequences cleaved using appropriate restriction enzymes. The fragments may then be ligated to produce the desired DNA sequence.

The nucleic acid sequences encoding the conjugates may be expressed in a variety of host cells, including *E. coli*, other bacterial hosts, yeast, and various higher eukaryotic cells such as the COS, CHO and HeLa cells lines and myeloma cell lines. The recombinant protein gene will be operably linked to appropriate expression control sequences for each host. For *E. coli* this includes a promoter such as the T7, *trp*, or lambda promoters, a ribosome binding site and preferably a transcription termination signal. For eukaryotic cells, the control sequences will include a promoter and preferably an enhancer derived from immunoglobulin genes, SV40, cytomegalovirus, etc., and a polyadenylation sequence, and may include splice donor and acceptor sequences.

Once expressed, the recombinant fusion proteins can be purified according to standard procedures of the art, including ammonium sulfate precipitation, affinity columns, column chromatography, gel electrophoresis and the like (see, generally, R. Scopes, *Protein Purification*, Springer-Verlag, N.Y. (1982), Deutscher, *Methods in Enzymology* Vol. 182. *Guide to Protein Purification*, Academic Press, Inc. N.Y. (1990)). Substantially pure compositions of at least about 90 to 95% homogeneity are preferred, and 98 to 99% or more homogeneity are most preferred for pharmaceutical uses. Once purified, partially or to homogeneity as desired, the polypeptides may then be used therapeutically.

The composition of the invention further comprises a pharmaceutically acceptable diluent or carrier. The compositions according to the invention will in practice normally be administered orally or by injection. As used herein "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents and the like. The use of such media and agents for pharmaceutical active substances is well known in the art. Except as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic composition is contemplated.

For oral administration tablets and capsules may contain conventional excipients, such as binders, for example syrup, sorbitol, or polyvinyl pyrrolidone; fillers, for example lactose, microcrystalline cellulose, corn starch, calcium phosphate or sorbitol; lubricants, for example magnesium stearate, stearic acid, polyethylene glycol or

silica; disintegrates, for example potato starch or sodium starch glycolate, or surfactants, such as sodium lauryl sulphate.

Oral liquid preparations can be in the form of for example water or oil
5 suspensions, solutions, emulsions, syrups or elixirs, or can be supplied as a dry product for constitution with water or another suitable vehicle before use.

The conjugate molecules of this invention are useful for parenteral, topical, oral, or local administration, such as by aerosol or transdermally. The pharmaceutical
10 compositions can be administered in a variety of unit dosage forms depending upon the method of administration; for example oral administration include powder, tablets, pills, capsules and lozenges. It is recognized that the pharmaceutical compositions of this invention, when administered orally, must be protected from digestion. This is typically accomplished either by complexing the conjugate with a composition to render it resistant
15 to acidic and enzymatic hydrolysis or by packaging the conjugate in an appropriately resistant carrier such as a liposome. Means of protecting proteins from digestion are well known in the art.

The pharmaceutical compositions of this invention are particularly useful for
20 parenteral administration, such as intravenous administration or administration into a body cavity or lumen of an organ. The compositions for administration will commonly comprise a solution of the conjugate molecule dissolved in a pharmaceutically acceptable carrier, preferably an aqueous carrier. A variety of aqueous carriers can be used, e.g., buffered saline and the like. These solutions are sterile and generally free of undesirable
25 matter. These compositions may be sterilized by conventional, well-known sterilization techniques. The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, toxicity adjusting agents and the like, for example, sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate and the like. The
30 concentration of the conjugate in these formulations can vary widely, and will be selected primarily based on fluid volumes, viscosities, body weight and the like in accordance with the particular mode of administration selected and the patient's needs.

Thus, a typical pharmaceutical composition for intravenous administration would be about 0.1 to 10 mg per patient per day. Dosages from 0.1 up to about 100 mg per patient per day may be used, particularly when the drug is administered to a secluded site and not into the blood stream, such as into a body cavity or into a lumen of an organ.

5 Actual methods for preparing parenterally administrable compositions will be known or apparent to those skilled in the art and are described in more detail in such publications as Remington's Pharmaceutical Science, 18th ed., Mack Publishing.

10 In therapeutic applications, compositions are administered to a patient suffering from a disease, in an amount sufficient to cure or at least partially arrest the disease and its complications. An amount adequate to accomplish this is defined as a "therapeutically effective dose." Amounts effective for this use will depend upon the severity of the disease and the general state of the patient's health. Single or multiple administrations of the compositions may be administered depending on the dosage and
15 frequency as required and tolerated by the patient. In any event, the composition should provide a sufficient quantity of the proteins of this invention to effectively treat the patient.

One of skill in the art will appreciate that the therapeutic compositions of this
20 invention can be administered directly to the tumor site. Thus, for example, brain tumors (e.g., gliomas) can be treated by administering the therapeutic composition directly to the tumor site (e.g., through a surgically implanted catheter). Where the fluid delivery through the catheter is pressurized, small molecules (e.g. the therapeutic molecules of this invention) will typically infiltrate as much as two to three centimeters beyond the tumor
25 margin. Alternatively, the therapeutic composition can be placed at the target site in a slow release formulation. Such formulations can include, for example, a biocompatible sponge or other inert or resorbable matrix material impregnated with the therapeutic composition, slow dissolving time release capsules or microcapsules, and the like.

30 Table 1 below summarizes the list of Sequence ID Numbers which appear in the application.

Table 1: Sequence listing

SEQ ID NO	Description	amino acid/nucleotide sequence
1	NKp46-Fc conjugate	Amino acids
2	NKp46D1-Fc conjugate	Amino acids
3	NKp46D2-Fc conjugate	Amino acids
4	NKp30-Fc conjugate	Amino acids
5	NKp44-Fc conjugate	Amino acids
6	NKp44DS-Fc conjugate	Amino acids
7	NKp44DL-Fc conjugate	Amino acids
8	NKp46-Fc conjugate	Nucleotides
9	NKp46D1-Fc conjugate	Nucleotides
10	NKp46D2-Fc conjugate	Nucleotides
11	NKp30-Fc conjugate	Nucleotides
12	NKp44-Fc conjugate	Nucleotides
13	NKp44DS-Fc conjugate	Nucleotides
14	NKp44DL-Fc conjugate	Nucleotides

5 SEQ ID NO:1 NKp46 (AJ001383 isoform a) protein

MSSTLPALLCVGLCLSQRISAAQQQTLPKPFIIWAEPHFMPVPEKEQVTICCGNYGAVEYQLHFEGSLFAVD
 RPKPPERINKVKFYIPDMNSRMAGQYSCIYRVGELWSEPSNLDDLVTETMDPTLSVHPGPEVISGEKV
 TFYCRDLDTATSMFLLLKEGRSSHVQRGYGVQAEFPLGPVTTAHRGTYRCFGSYNNHAWSFSEPVKLLV
 10 TGDIENTSLAPEDPTFPADTWGTYLLTTETGLQKDHLDHTAQDPEPKSSDKTHTCPPCPAPEFEGAPSVF
 LFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDW
 LNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNG
 QPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

15 Black letters designate origin leader peptide
 Underlined letters designate D1 region
 Bold letters designate D2 region
 Italic letters designate Fc region (234 amino acid)

20 SEQ ID NO: 2 NKp46-D1 stable amino acid seq.

MGMPMGSLQPLATLYLLGMLVASCLGRLRVPQQQTLPKPFIIWAEPHFMPVPEKEQVTICCGNYGAVEYQL
 HFEGSLFAVDRPKPPERINKVKFYIPDMNSRMAGQYSCIYRVGELWSEPSNLDDLVTETMDPEPKSSDKT
 25 HTCPPCPAPEFEGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRE
 EQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQV
 SLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALH
 NHYTQKSLSLSPGK

30 Black letters designate leader peptide of CD5
 Underlined letters designate KpnI site (5 amino acid)
 Bold letters designate D1 region
 Italic letters designate Fc region (234 amino acid)

35 SEQ ID NO:3 NKp46-D2 stable amino acid seq.

MGMPMGSLQPLATLYLLGMLVASCLGRLRVPYDPTLSVHPGPEVISGEKVTFYCRDLDTATSMFLLLKEG
 RSSHVQRGYGVQAEFPLGPVTTAHRGTYRCFGSYNNHAWSFSEPVKLLVTGDIENTSLAPEDPTFPDT
 WGTYLLTTETGLQKDHLDHTAQDPEPKSSDKTHTCPPCPAPEFEGAPSVFLFPPKPKDTLMISRTPEVTCVVVDV
 SHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISK

AKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

- 5 Black letters designate leader peptide of CD5
Underlined letters designate *KpnI* site (5 amino acid)
Bold letters designate D2 region (128 amino acid)
Italic letters designate Fc region (234 amino acid)

SEQ ID NO:4 NKp30 stable amino acid seq.

- 10 MGMPMGSLQPLATLYLLGMLVASCLGRLRVPLWVS**QPLE**IRTLEGSSAFLPCSFNASQGR**LAIGSVTWFR**
DEVVPGKEVRNGTPEFRGR**LAPLASSRFLHDHQAELH**IRDVRGH**DASIYVCRVEVLGLGVGTGNGTRLV**
EKEHPQLGDPEPKSSDKTHTCPPCPA**FEFEGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKF**
NWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK**TISKAKGQPRE**
15 *PQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK*

- 20 Black letters designate leader peptide of CD5
Underlined letters designate *KpnI* site (5 amino acid)
Bold letters designate NKp30
Italic letters designate Fc region

SEQ ID NO:5NKp44 stable amino acid seq.

- 25 MGMPMGSLQPLATLYLLGMLVASCLGRLRV**QSKAQVLQSVAGQTLTVRCQY**PPTGSLYEKKGWCKEASA
LVCIRLV**TSSKPRTVAWTSRFTIWDDPDAGFFT**VTMTDLREEDSGHYWCRIYRPSD**NSVSKSVRFYLVVS**
PASAST**QTSWTPRDLVSSQTQTQSCVPPTAGARQAPES**PS**TIPVPSQPQNSTLRPGPAAPDPEPKSSDKT**
HTCP**PCPAFEFEGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRE**
EQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK**TISKAKGQPREPQVYTLPPSRDELTKNQV**
30 *SLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK*

- 35 Black letters designate leader peptide of CD5
Underlined letters designate *KpnI* site(5 amino acid)
Bold letters designate NKp44 region
Italic letters designate Fc region(234aminoacid)

SEQ ID NO:6 NKp44-DS stable amino acid seq.

- 40 MGMPMGSLQPLATLYLLGMLVASCLGRLRV**SPASASTQTSWTPRDLVSSQTQTQSCVPPTAGARQAPES**
PSTIPVPSQPQNSTLRPGPAAPDPEPKSSDKTHTCPPCPA**FEFEGAPSVFLFPPKPKDTLMISRTPEVTC**
VVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAP
45 *IEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK*

- 50 Black letters designate leader peptide of CD5
Underlined letters designate *KpnI* site(5 amino acid)
Bold letters designate NKp44-DS region
Italic letters designate Fc region(234aminoacid)

SEQ ID NO:7 NKp44-DL stable amino acid seq

- 55 MGMPMGSFQPLATLYLLGMLVASCLGRLRV**QSKAQVLQSVAGQTLTVRCQY**PPTGSLYEKKGWCKEASA
LVCIRLV**TSSKPRTVAWTSRFTIWDDPDAGFFT**VTMTDLREEDSGHYWCRIYRPSD**NSVSKSVRFYLVVS**
PADPEPKSSDKTHTCPPCPA**FEFEGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDG**

VEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTL
PPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQOGN
VFSCSVMEALHNHYTQKSLSLSPGK

5

Black letters designate leader peptide of CD5
Underlined letters designate KpnI site(5 amino acid)
Bold letters designate NKp44-DL region
Italic letters designate Fc region(234aminoacid)

10

SEQ ID NO:8 NKp46 DNA seq. (AJ001383)

15 TCCCCACTGCTCAGCACTTAGGCCGGCAGAATCTGAGCGATGTCTTCCACACTCCCTGCCCTGCTCTGCG
TCGGGCTGTGTCTGAGTCAGAGGATCAGCGCCAGCAGCAGACTCTCCAAAACCGTTTCATCTGGGCCGA
GCCCCATTTTCATGGTTCCAAAGGAAAAGCAAGTGACCATCTGTTGCCAGGGAAATTATGGGGCTGTTGAA
TACCAGCTGCACCTTTGAAGGAAGCCTTTTTTGCCGTGGACAGACCAAAAACCCCTGAGCGGATTAACAAAG
TCAAATTCTACATCCCGGACATGAACCTCCCGCATGGCAGGGCAATACAGCTGCATCTATCGGGTTGGGGA
GCTCTGGTCAGAGCCCAGCAACTTGCTGGATCTGGTGGTAACAGAAATGTATGACACACCCACCCCTCTCG
20 GTTCATCCTGGACCCGAAGTGATCTCGGGAGAGAAGGTGACCTTCTACTGCCGTCTAGACACTGCAACAA
GCATGTTCTTACTGCTCAAGGAGGGAAGATCCAGCCACGTACAGCGCGGATACGGGAAGGTCCAGGCGGA
GTTCCCCCTGGGCCCTGTGACCACAGCCCACCGAGGGACATACCGATGTTTTGGCTCCTATAACAACCAT
GCCTGGTCTTTCCCCAGTGAGCCAGTGAAGTCTTGGTTCACAGGCGACATTGAGAACACCAGCCTTGAC
CTGAAGACCCCACTTTTCTGCAGACACTTGGGGCACCTACCTTTTAACCACAGAGACGGGACTCCAGAA
25 AGACCATGCCCTCTGGGATCACACTGCCAGGATCCGGAGGCCAAATCTTCTGACAAAACCTCACACATGC
CCACCGTGCCCGAGCACCTGAATTCGAGGGTGCACCGTCAGTCTTCTCTTCCCCCAAAACCCAAGGACA
CCCTCATGATCTCCCGGACCCCTGAGGTACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCCTGAGGT
CAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTAC
AACAGCACGTACCGTGTGGTCAGCGTCTCACCCTGCTGCACCAGGACTGGCTGAATGGCAAGGAGTACA
30 AGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCATCGAGAAAACCATCTCCAAGCCAAAGGGCAGCC
CCGAGAGCCACAGGTGTACACCTGCCCCCATCCCGGATGAGCTGACCAAGAACCAGGTACAGCTGACC
TGCTTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACA
ACTACAAGACCACGCCTCCCGTGTGGACTCCGACGGCTCCTTCTTCTCTACAGCAAGCTCACCGTGGA
CAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTAC
35 ACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAATGA

35

SEQ ID NO:9 NKp46-D1 stable DNA seq. in pCDNA3.1

40 AAGCTTGCCGCCACCATG**G**GAATGCCCATGGGGTCTCTGCAACCGCTGGCCACCTTGTACCTGCTGGGGA
TGCTGGTTCGCTTCCCTGCGACGGCTCAGGGTACCCAGCAGCAGACTCTCCAAAACCGTTTCATCTG
GGCCGAGCCCCATTTTCATGGTTCCAAAGGAAAAGCAAGTGACCATCTGTTGCCAGGGAAATTATGGGGCT
GTTGAATACCAGCTGCACCTTTGAAGGAAGCCTTTTTTGCCGTGGACAGACCAAAAACCCCTGAGCGGATTA
ACAAAGTCAAATTCTACATCCCGGACATGAACCTCCCGCATGGCAGGGCAATACAGCTGCATCTATCGGGT
TGGGGAGCTCTGGTCAGAGCCCAGCAACTTGCTGGATCTGGTGGTAACAGAAATGGATCCGGAGCCCAA
45 TCTTCTGACAAAACCTCACACATGCCACCGTGCCAGCACCTGAATTCGAGGGTGCACCGTCAGTCTTCC
TCTTCCCCCAAAACCCAAGGACACCCCTCATGATCTCCCGGACCCCTGAGGTACATGCGTGGTGGTGA
CGTGAGCCACGAAGACCCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAG
ACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTTCAGCGTCTCACCCTGCTGCACCAGG
ACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAGCCCTCCCAGCCCCATCGAGAAAAC
CATCTCCAAGCCAAAGGGCAGCCCCGAGAGCCACAGGTGTACACCCTGCCCGGATGAGCTG
50 ACCAAGAACCAGGTACAGCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGG
AGAGCAATGGGCAGCCGGAGAACAACATAAGACCACGCCTCCCGTGTGGACTCCGACGGCTCCTTCTT
CCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATG
CATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAATGA

55

Black letters designate HindIII site
Open box designate Kozak seq.(with the G in position +4)
Underlined letters designate Start codon of the CD5 leader peptide
Bold letters designate CD5 leader peptide
Shaded letters designate KpnI site

Underlined letters designate D1 DNA seq.
 Italic letters designate Fc DNA seq.

SEQ ID NO:10 NKp46-D2 stable DNA seq. in pCDNA3.1

5 AAGCTTGCCGCCACCATG**G**GAATGCCCATGGGGTCTCTGCAACCGCTGGCCACCTTGTACCTGCTGGGGA
 TGCTGGTTCGCTTCCTGCCTCGGACGGCTCAGGGTACCCCTATGACACACCCACCCTCTCGGTTTCATCTGG
 ACCCGAGGTGATCTCGGGAGAGAAGGTGACCTTCTACTGCCGTCTAGACACTGCAACAAGCATGTTCTTA
 10 CTGCTCAAGGAGGGAAGATCCAGCCACGTACAGCGCGGATACGGGAAGGTCCAGGCGGAGTTCCCCCTGG
 GCCCTGTGACCACAGCCACCGAGGGACATACCGATGTTTTGGCTCCTATAACAACCATGCCTGGTCTTT
 CCCCAGTGAGCCAGTGAAGCTCCTGGTCACAGCGCATATTGAGAACACCAGCCTTGCACCTGAAGACCCC
 ACCTTTCTTGACACTTGGGGCACCTACCTTTTAAACCACAGAGACGGGACTCCAGAAAGACCATGCCCTCT
 GGGATCCGGAGCCCAAATCTTCTGACAAAACCTACACATGCCACCGTGCCAGCACCTGAATTCGAGGG
 15 TGCACCGTCAGTCTTCTTCTTCCCCCAAACCCAAGGACACCCCTCATGATCTCCCGGACCCCTGAGGTC
 ACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGG
 AGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCTCT
 CACCGTCTTGACACAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCA
 GCCCCCATCGAGAAAACCATCTCCAAGCCAAAGGGCAGCCCCGAGAGCCACAGGTGTACACCCTGCCCC
 20 CATCCCGGGATGAGCTGACCAAGAACCAGGTACGCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGA
 CATCCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAACAACACTACAAGACCACGCCTCCCGTGTGGAC
 TCCGACGGCTCCTTCTTCTTCTTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCT
 TCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGG
 TAAATGA

25 Black letters designate HindIII site
 Open box designate Kozak seq. (with the G in position+4)
 Underlined letters designate Start codon of the CD5 leader peptide
 Bold letters designate CD5 leader
 Shaded letters designate KpnI site
 30 Underlined letters designate D2 DNA seq.
 Italic letters designate Fc DNA seq.

SEQ ID NO:11 NKp30 stable DNA seq. in pCDNA3.1

35 AAGCTTGCCGCCACCATG**G**GAATGCCCATGGGGTCTCTGCAACCGCTGGCCACCTTGTACCTGCTGGGGA
 TGCTGGTTCGCTTCCTGCCTCGGACGGCTCAGGGTACCCCTCTGGGTGTCCAGCCCCCTTGAGATTTCGTAC
 CCTGGAAGGGTCTTCTGCCTTCTTGCCTGCTCCTTCAATGCCAGCCAAGGGAGACTGGCCATTGGCTCC
 40 GTCACGTGGTTCCGAGATGAGGTGGTTCCAGGGAAGGAGGTGAGGAATGGAACCCAGAGTTGAGGGGCC
 GCCTGGCCCCACTTGCTTCTTCCCGTTTCCCTCCATGACCACCAGGCTGAGCTGCACATCCGGACAGTGGCG
 AGGCCATGACGCCAGCATCTACGTGTGCAGAGTGGAGGTGCTGGGCCTTGGTGTCCGGACAGGGAATGGG
 ACTCGGCTGGTGGTGGAGAAAGACATCCTCAGCTAGGGGATCCGGAGCCCAAATCTTCTGACAAAACCT
 ACACATGCCACCGTGCCAGCACCTGAATTCGAGGGTGCACCGTCAGTCTTCTTCTTCCCCCAAACCC
 CAAGGACACCCCTCATGATCTCCCGGACCCCTGAGGTACATGCGTGGTGGTGGACGTGAGCCACGAAGAC
 45 CCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGG
 AGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCTCACCGTCTGCACCAAGGACTGGCTGAATGGCAA
 GGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCAGCCCCCATCGAGAAAACCATCTCCAAGCCAAA
 GGGCAGCCCCGAGAGCCACAGGTGTACACCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCA
 GCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCCCGGTGGAGTGGGAGAGCAATGGGCAGCC
 50 GGAGAACAACACTACAAGACCACGCCTCCCGTGTGGACTCCGACGGCTCCTTCTTCTTCTACAGCAAGCTC
 ACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACA
 ACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAATGA

55 Black letters designate HindIII site
 Open box designate Kozak seq. (with the G in position +4)
 Underlined letters designate Start codon of the CD5 leader peptide
 Bold letters designate CD5 leader
 60 Shaded letters designate KpnI site

Underlined letters designate 30 DNA seq.
 Italic letters designate Fc DNA seq.

5 SEQ ID NO:12 NKp44 stable DNA seq. in pCDNA3.1

AAGCTTGCCGCCACCATGGAATGCCCATGGGGTCTCTGCAACCGCTGGCCACCTTGTACCTGCTGGGGA
 TGCTGGTTCGCTTCCTGCCTCGGACGGCTCAGGGTACCCCAATCCAAGGCTCAGGTACTTCAAAGTGTGGC
 10 AGGGCAGACGCTAACCGTGAGATGCCAGTACCCGCCACGGGCAGTCTCTACGAGAAGAAAGGCTGGTGT
AAGGAGGCTTCAGCACTTGTGTGCATCAGGTTAGTACACAGCTCCAAGCCCAGGACGGTGGCTTGGACCT
CTCGATTACAATCTGGGACGACCCTGATGCTGGCTTCTTCACTGTCACCATGACTGATCTGAGAGAGGA
AGACTCAGGACATTACTGGTGTAGAATCTACCGCCCTTCTGACAACTCTGTCTCTAAGTCCGTGAGATTC
TATCTGGTGGTATCTCCAGCCTCTGCCTCCACACAGACCTCCTGGACTCCCCGCGACCTGGTCTCTTCAC
AGACCCAGACCCAGAGCTGTGTGCCTCCCACTGCAGGAGCCAGACAAGCCCCCTGAGTCTCCATCTACCAT
 15 CCCTGTCCCTTCACAGCCACAGAACTCCACGCTCCGCCCTGGCCCTGCAGCCCCGATCCGGAGCCCCAA
TCTTCTGACAAAACCTCACACATGCCCACCGTGCCAGACCTGAATTCGAGGGTGCACCGTCAGTCTTCC
TCTTCCCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGGA
CGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAG
ACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCTCACCCTCCTGCACCAGG
 20 ACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCAGCCCCCATCGAGAAAAC
CATCTCCAAAGCCAAAGGGCAGCCCCGAGAGCCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTG
ACCAAGAACCAGGTGAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCAGCGACATCGCCGTGGAGTGGG
AGAGCAATGGGCAGCCGGAGAACAATAACAAGACCACGCCTCCCGTGTGGACTCCGACGGCTCCTTCTT
CCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATG
 25 CATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAATGA

Black letters designate HindIII site

Open box designate Kozak seq.(withtheGinposition+4)

Underlined letters designate Start codon of the CD5 leader peptide

30 Bold letters designate CD5 leader

Shaded letters designate KpnI site

Underlined letters designate NKp44 DNA seq.

Italic letters designate Fc DNA seq.

35

SEQ ID NO:13 NKp44-DS stable DNA seq. in pCDNA3.1

AAGCTTGCCGCCACCATGGAATGCCCATGGGGTCTCTGCAACCGCTGGCCACCTTGTACCTGCTGGGGA
 40 TGCTGGTTCGCTTCCTGCCTCGGACGGCTCAGGGTACCCCTCTCCAGCCTCTGCCTCCACACAGACCTCCTG
ACTCCCCGCGACCTGGTCTCTTACAGACCCAGACCCAGAGCTGTGTGCCTCCCACTGCAGGAGCCAGA
CAAGCCCCCTGAGTCTCCATCTACCATCCCTGTCCCTTACAGCCACAGAACTCCACGCTCCGCCCTGGCC
CTGCAGCCCCGATCCGGAGCCCAAATCTTCTGACAAAACCTCACACATGCCCACCGTGCCAGCACCTGA
 45 ATTCGAGGGTGCACCGTCAGTCTTCTTCTTCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACC
CCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGG
ACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGT
CAGCGTCTCACCCTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAA
GCCCTCCAGCCCCCATCGAGAAAACCATCTCCAAGCCAAAGGGCAGCCCCGAGAGCCACAGGTGTACA
 50 CCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTGAGCCTGACCTGCCTGGTCAAAGGCTTCTA
TCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAATAACAAGACCACGCCTCCC
GTGCTGGACTCCGACGGCTCCTTCTTCTTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGG
GGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCT
GTCTCCGGGTAAATGA

55 Black letters designate HindIII site

Open box designate Kozak seq.(withtheGinposition+4)

Underlined letters designate Start codon of the CD5 leader peptide

Bold letters designate CD5 leader

Shaded letters designate KpnI site

60 Underlined letters designate NKp44-DS DNA seq.

Italic letters designate Fc DNA seq.

SEQ ID NO:14 NKp44-DL stable DNA seq. in pCDNA3.1

5 AAGCTT[GCCGCCACC]ATG[G]GAATGCCCATGGGGTCTCTGCAACCGCTGGCCACCTTGTACCTGCTGGGGA
 TGCTGGTCGCTTCTCGCTCGGACGGCTCAGGGTACCCCAATCCAAGGCTCAGGTACTTCAAAGTGTGGC
 AGGGCAGACGCTAACCCTGAGATGCCAGTACCCGCCCCACGGGCAGTCTCTACGAGAAGAAAGGCTGGTGT
 AAGGAGGCTTCAGCACTTGTGTGCATCAGGTTAGTCACCAGCTCCAAGCCCAGGACGGTGGCTTGGACCT
 CTCGATTCACAATCTGGGACGACCCTGATGCTGGCTTCTTCACTGTCACCATGACTGATCTGAGAGAGGA
 10 AGACTCAGGACATTACTGGTGTAGAATCTACCGCCCTTCTGACAACTCTGTCTCTAAGTCCGTCAGATTC
 TATCTGGTGGTATCTCCAGCGGATCCGGAGCCCCAAATCTTCTGACAAAACTCACACATGCCCCACCGTGCC
 CAGCACCTGAATTCGAGGGTGCACCGTCAGTCTTCTCTTCCCCCAAAACCCAAGGACACCCTCATGAT
 CTCCCGGACCCCTGAGGTACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCCTGAGGTCAAGTTCAAC
 TGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGT
 15 ACCGTGTGGTCAGCGTCCCTACCGTCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGAAGGT
 CTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAGCCA
 CAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCA
 AAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAATAAGAC
 CACGCCTCCCGTGTGGACTCCGACGGCTCCTTCTTCTCTACAGCAAGCTCACCGTGGACAAGAGCAGG
 20 TGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGA
 GCCTCTCCCTGTCTCCGGGTAAATGA

Black letters designate HindIII site

Open box designate Kozak seq. (with the G in position +4)

25 Underlined letters designate Start codon of the CD5 leader peptide

Bold letters designate CD5 leader

Shaded letters designate KpnI site

Underlined letters designate NKp44-DL DNA seq.

Italic letters designate Fc DNA seq.

30

The following examples are presented in order to more fully illustrate certain embodiments of the invention. They should in no way, however, be construed as limiting the broad scope of the invention. One skilled in the art can readily devise many variations and modifications of the principles disclosed herein without departing from the scope of the invention.

EXAMPLES

40 Experimental Methods:

Preparation of NKpi-Ig conjugates

Sequences encoding the extracellular portions of NKp30, NKp44 and NKp46 were amplified by PCR from cDNA isolated from human NK clones. These PCR-generated fragments were cloned into the mammalian expression vector containing the constant region (Hinge+CH2+CH3) of a human IgG1 heavy chain. The Ig-conjugates (termed as

NKpi-Ig) were produced by transfection of mammalian cells (e.g. COS-7). Protein dimers were secreted from transfected cells (grown in medium without serum), and were purified from the supernatant using Protein-G columns. Protein-G binds only to Fc portion of the dimers made of Ig heavy chain constant regions; thus only the dimers of NKpi-Ig were purified.

Preparation of NKpi-Ig stable clones for constant expression

Sequences encoding the extracellular portions of NKp30-Ig, NKp44-Ig, NKp46-Ig, NK46D2-Ig and CD99-Ig as a control protein were amplified by PCR from cDNA isolated from human NK clones, using Kozak primer for high expression. These PCR fragments containing Kozak sequence and leader sequence were cloned into pCDNA3.1-Ig vector. CHO cells were transfected with these expression vectors and were selected using G418 antibiotic. Selected clones were screened for highest protein production using ELISA. High producer clones were re-cloned and screened again for highest protein production. One clone was adapted for special serum-free medium followed by optimization for growth in large-scale culture using spinner basket-Fibro cell (New Brunswick) or triple flasks. Supernatant were collected daily for purification on protein-G columns using FPLC.

Analysis of various prostate cancer cells for NCR binding

Expression of ligands to NCRs was quantitated by flow cytometry analysis of NKpi-Ig binding to various prostate cancer cells. Cells were incubated with 10 micrograms of each NKpi-Ig followed by incubation with human Fc-specific-(PE)-conjugated goat-anti-human IgG. MFI indicates Median Fluorescence Intensity; MFI numbers were rounded to the nearest whole numbers. Results are representative of two independent experiments.

Testing the therapeutic efficacy of NKpi-Ig on prostate cancer and melanoma growth in vivo

PC-3 human prostate cancer cells were transfected with plasmid encoding the luciferase gene. Nude mice were injected with PC-3-luciferase cells and monitored for tumor growth twice a week. Tumor growth was monitored using whole-body imaging with a charged-coupled device camera. For real time monitoring of tumor development, mice were anesthetized and injected intraperitoneally with 50 mM luciferin (126 mg/Kg). Bioluminescence was monitored 1 min later, using an intensified charged coupled device

camera (model U 6173-01; Hamamatusu, Hamamatusu, Japan). After establishment of tumor, NKpi-Ig was injected daily (0.25 mg / mouse / day) and the growth of tumors in treated and mock-treated mice was monitored.

5

Example 1: Binding of NKpi-Ig to various cancer cells but not to normal peripheral blood lymphocytes (PBL).

In order to measure the specific NKpi-Ig binding to various tumor cells, cells
10 were incubated with different Ig-conjugates and stained with PE-conjugated goat anti-human Fc. As demonstrated in Figure 1, different human tumor cell lines (such as cell lines derived from Melanoma (1074mel, 1259mel, MELA1, 1106mel), Chronic Myelogenous Leukemia (CML) (K562), Prostate carcinoma (PC3-Luc, PC3, DU145), weakly EBV-transformed B cells (RPMI8866, 721.221)) were recognized by the various
15 lysis receptors NKp46, NKp44 and NKp30 conjugates. Primary tumor cells were also recognized by the various conjugates, including melanoma and CML cells. No specific NKpi-Ig binding was found in peripheral blood lymphocytes (PBL) normal cells, indicating the specific binding of NKpi-Ig to tumor cells. In addition, T cell lymphoma (Jurkat) and primary breast carcinoma were recognized mainly by NKp30 and NKp44
20 and to a lesser extent by NKp46.

The next step was to test conjugates containing the first domain of NKp46 (NKp46-D1-Ig) or the second domain of NKp46 (NKp46-D2-Ig) in their ability to bind specifically to tumor cells. Figure 2 demonstrates the binding of the NKp46-D1-Ig and
25 NKp46-D2-Ig conjugates to Melanoma cell lines and prostate cancer cell lines. As can be observed, no significant binding of NKp46-D1-Ig was detected to any of the target cells tested. In contrast, binding of NKp46-D2-Ig was observed to the entire cell lines tested. These findings indicate that NKp46D2-Ig has a better binding capability comparing with NKp46-Ig and NKp30-Ig. Table 2 summarizes the binding profile of NKp30 and NKp46
30 (30ug/ml) to various tumor cell lines as determined by FACS analysis. As control for Ig fusion protein CTLA-4 Ig was used for the carcinomas, in the case of lymphomas E7-Ig was used.

Table 2: Binding of NKp30 and NKp46 to tumor cell lines

Category	Designation	Histological Type	NKp46	NKp30
Breast	MDA-MB 231	Adenocarcinoma	Positive	Negative
Colon	HCT116	Adenocarcinoma	Negative	Negative
Colon	HT29	Adenocarcinoma	Positive	Positive
Lung	A-549	Large cell carcinoma	Negative	Negative
Prostate	LN-Cap	Metastatic carcinoma, androgen dependent	Positive	Positive
Prostate	PC-3	Carcinoma, androgen independent	Positive	Positive
B Lymphoma	SKW	EBV positive, B lymphoma	Negative	Negative
B Lymphoma	Raji	Burkitt's Lymphoma	Negative	Positive
B Lymphoma	Ramos	Burkitt's Lymphoma	Negative	Negative

5

Example 2: Macrophage-mediated Antigen-Dependent Cellular Cytotoxicity of tumor cells with NKp30-Ig and NKp46D2-Ig

As revealed from Figure 3, the binding of NKp46D2-Ig and NKp30-Ig conjugates to their unknown ligands on PC3 prostate cancer cells mediates the lysis of the cancer cells via macrophage-dependent lysis mechanism. In vitro killing of PC3 cells coated with the NKp30-Ig or NKp46D2-Ig conjugates by complement and NK cells was not observed.

10

Example 3: In vivo tumor cell elimination after treatment with NKp30-Ig.

Mice were inoculated S.C. with 2×10^6 PC-3 human prostate cancer cells transfected with plasmid encoding the luciferase gene. Tumor growth was monitored using whole-body imaging with a charge-coupled device camera. After detectable tumors were established, mice were divided into two groups with similar tumor size distribution. One group received the test conjugate and the other received vehicle control for 3 weeks and the mice were sacrificed. For the test group, NKp30-Ig was injected intraperitoneally daily (0.25 mg /mouse/day) for 3 weeks and the mice were sacrificed. The growth of tumors in treated and mock-treated mice was monitored twice a week. As revealed from Figure 4 and Table 3, the treatment with NKp30-Ig mediated tumor regression in prostate cancer-bearing nude mice.

15

20

Table 3: Tumor regression following the treatment with NKp30-Ig.

Treatment	Partial regression (less than 50%)	Regression (over 50%)	Progressive growth of tumor
Control	1/6	1/6	4/6
NKp30-Ig	1/7	5/7	1/7

5

Table 4 demonstrates the results following a multiple-dose treatment of NKp30-Ig compared to NKp46D2-Ig on PC3 tumors in nude mice.

10 **Table 4:** Tumor cell elimination following a multiple-dose treatment of NKp30-Ig and NKp46D2-Ig

Treatment	Complete response	Partial response	Progressive growth of tumor
Control	0/8	1/8	7/8
NKp30-Ig	7/17	5/17	5/7
NKp46D2-Ig	2/9	1/9	6/9

15 A large-scale experiment was designed to compare the effects of NKp30-Ig and NKp46D2-Ig on growth of tumors in nude mice injected with PC3 prostate cell line. The PC3 cells were injected and three weeks later when tumors were visible, treatments were initiated. As shown in Table 4, the treatment with NKp30-Ig results in complete or partial regression in about two thirds of the mice. Figure 5 illustrates the response obtained using the NKp30-Ig conjugate as revealed by the size of the tumor. Treatment with NKp46D2-Ig had no discernable effect on tumor growth in this set of experiments (Table 4).

20

Example 4: NKp46D2-Ig binding is followed by its internalization to the intracellular domain.

25 In order to examine whether the NKp46D2-Ig conjugate can be internalized into the target tumor cell, NKp46D2-Ig was incubated with 1106mel and PC3 cell lines followed by fluorescent dye, which can be monitored by confocal microscopy. Conditions suitable for internalization of receptors were applied. Figure 6 demonstrates that NKp46D2-Ig bind to its ligand on the cell surface of 1106mel cells and then is internalized into the intracellular domain. The same was demonstrated in PC3 cell line, NKp46D2-Ig is located in the intracellular domain after binding to its ligands on PC3 cell
30 line.

Example 5: Immunohistochemistry staining of NKp46D2-Ig and NKp30-Ig performed on normal and tumor Paraffin-embedded tissues

Immunohistochemistry staining of NKp46D2-Ig and NKp30-Ig performed on different normal and tumor tissues was conducted. As demonstrated in Table 5, Paraffin-embedded tissues derived from tumors positively react with NKp46D2-Ig and NKp30-Ig. Normal tissues demonstrated negative results in the majority of the examined tissues. Pancreatic islet and chief cells in stomach fundus were the only normal cells that were stained by NKp46D2-Ig.

Table 5: Immunohistochemistry staining of NKp46D2-Ig and NKp30-Ig performed on different normal and tumor paraffin embedded tissues.

Tissue	Positive
Subcutaneous tissue	Angiosarcoma
Breast	Ductal carcinoma in situ
Breast	Infiltrating duct carcinoma
Lymph node	Hodgkin's disease
Bone	Osteosarcoma
Lung	Adenocarcinoma
Liver	Cholangiocarcinoma
Liver	Metastatic adenocarcinoma, rectum
Duodenum	Stromal tumor, malignant
Sigmoid colon	Adenocarcinoma
Rectum	Adenocarcinoma
Rectum	Mucinous carcinoma
Kidney	Renal cell carcinoma
Bladder	Transitional cell carcinoma
Myometrium	Leiomyoma
Ovary	Metastatic mucinous adenocarcinoma, appendix
Ovary	Mucinous cyst adenocarcinoma
Thyroid	Papillary carcinoma
Skin	Malignant melanoma

Pathologists use the Gleason system to evaluate the differentiation of the adenocarcinoma tissue in the prostate. It is based exclusively on the architectural pattern of the glands of the prostate tumor. It evaluates how effectively the cells of any particular cancer are able to structure themselves into glands resembling those of the normal

prostate. The ability of a tumor to mimic normal gland architecture is called its differentiation, and experience has shown that a tumor whose structure is nearly normal (well differentiated) will probably have a biological behavior relatively close to normal -- that is not very aggressively malignant. The principle is fairly simple, and Gleason
5 grading from very well differentiated to very poorly differentiated. The lower the Gleason score, the better the patient is likely to survive.

Figure 7 demonstrates immunohistochemical staining with two prostate adenocarcinomas, one with score 8 and the second with score 6, the last prostate was a
10 benign prostatic hyperplasia (BPH) that in elder man consider to be a "normal" prostate. As revealed from Figure 7, strong binding of NKp46D2-Ig and NKp30-Ig to the adenocarcinoma and not to the BPH was observed. It is important to note that when the BPH is in the vicinity of an adenocarcinoma it would be stained with NKp46D2-Ig and NKp30-Ig. These findings are unique because it means that the NKp30-Ig and NKp46D2-
15 Ig conjugates can detect tumor-associated changes in the benign hyperplasia in the prostate.

The same pattern was found in melanoma and in pancreatic cancer. As demonstrated in Figure 8, NKp30-Ig and NKp46D2-Ig bind to malignant melanoma and not to benign nevus which is an early stage of potential melanoma. It is thus another
20 example in which NKp46D2-Ig uniquely and selectively binds to the malignant cancers and to the normal tissues surrounding the tumor and not to benign lesions. Similarly, Figure 9 demonstrates that NKp46D2-Ig specifically recognizes the tissue derived from pancreatic cancer, one of the most lethal cancers in humans. NKp46D2-Ig binds specifically to pancreatic cancer cells that originate from acinar cells in the pancreas.

25

References:

1. Trinchieri, G. 1989. Biology of natural killer cells. *Adv Immunol* 47:187-376.
2. Long, E.O. 2002. Tumor cell recognition by natural killer cells. *Semin Cancer Biol*
30 12:57-61.

3. Biassoni, R., C. Cantoni, D. Pende, S. Sivori, S. Parolini, M. Vitale, C. Bottino, and A. Moretta. 2001. Human natural killer cell receptors and co-receptors. *Immunol Rev* 181:203-214.
- 5 4. Bakker, A.B., J. Wu, J.H. Phillips, and L.L. Lanier. 2000. NK cell activation: distinct stimulatory pathways counterbalancing inhibitory signals. *Hum Immunol* 61:18-27.
- 10 5. Moretta, A., C. Bottino, M. Vitale, D. Pende, C. Cantoni, M.C. Mingari, R. Biassoni, and L. Moretta. 2001. Activating receptors and coreceptors involved in human natural killer cell-mediated cytotoxicity. *Annu Rev Immunol* 19:197-223.
6. Ljunggren, H.G., and K. Karre. 1990. In search of the 'missing self': MHC molecules and NK cell recognition. *Immunol Today* 11:237-244.
- 15 7. McQueen, K.L., and P. Parham. 2002. Variable receptors controlling activation and inhibition of NK cells. *Curr Opin Immunol* 14:615-621.
- 20 8. Pessino A, Sivori S, Bottino C, Malaspina A, Morelli L, Moretta L, Biassoni R, Moretta A. Molecular cloning of NKp46: a novel member of the immunoglobulin superfamily involved in triggering of natural cytotoxicity. *J Exp Med*. 1998;188:953-960.
- 25 9. Vitale M, Bottino C, Sivori S, Sanseverino L, Castriconi R, Marcenaro E, Augugliaro R, Moretta L, Moretta A. NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis. *J Exp Med*. 1998;187:2065-2072.
- 30 10. Cantoni C, Bottino C, Vitale M, Pessino A, Augugliaro R, Malaspina A, Parolini S, Moretta L, Moretta A, Biassoni R. NKp44, a triggering receptor involved in tumor cell lysis by activated human natural killer cells, is a novel member of the immunoglobulin superfamily. *J Exp Med*. 1999;189:787-796.

11. Sivori S, Pende D, Bottino C, Marcenaro E, Pessino A, Biassoni R, Moretta L, Moretta A. NKp46 is the major triggering receptor involved in the natural cytotoxicity of fresh or cultured human NK cells. Correlation between surface density of NKp46 and natural cytotoxicity against autologous, allogeneic or xenogeneic target cells. Eur J Immunol. 1999;29:1656-1666.
12. Costello RT, Sivori S, Marcenaro E, Lafage-Pochitaloff M, Mozziconacci MJ, Revirion D, Gastaut JA, Pende D, Olive D, Moretta A. Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. Blood. 2002;99:3661-3667.

It will be appreciated by a person skilled in the art that the present invention is not limited by what has been particularly shown and described hereinabove. Rather, the scope of the invention is defined by the claims that follow.

CLAIMS:**1.** A polypeptide conjugate comprising:

(a) a target recognition segment comprising a Natural Killer cell receptor (NCR) or an active fragment thereof, wherein the NCR is selected from the group consisting of: NKp30 or a functional fragment thereof that binds to a cellular ligand expressed on the surface of a target tumor cell; and

(b) a second segment comprising an active agent capable of exerting a cytotoxic effect on the target cell.

2. The conjugate according to claim 1, wherein the active agent is selected from the group consisting of: a cytotoxic agent, an immunoglobulin (Ig) molecule and a fragment thereof.

3. The conjugate according to claim 2, wherein the active agent is the Fc fragment of the immunoglobulin molecule.

4. The conjugate according to claim 3, wherein the conjugate comprises NKp30 covalently attached to the Fc fragment of an Ig molecule.

5. The conjugate according to claim 4, having the amino acid sequence as set forth in SEQ ID NO:4 or functional fragments thereof.

6. An isolated polynucleotide encoding a polypeptide conjugate, the conjugate comprises:

(a) a target recognition segment comprising a Natural Killer cell receptor (NCR) or an active fragment thereof, wherein the NCR is selected from the group consisting of: NKp30 or a functional fragment thereof that binds to a cellular ligand expressed on the surface of a target tumor cell; and

(b) a second segment comprising an active agent capable of exerting a cytotoxic effect on the target cell.

7. The isolated polynucleotide according to claim 6, wherein the active agent is selected from the group consisting of: a cytotoxic agent, an Ig molecule and a fragment thereof.

8. The isolated polynucleotide according to claim 7, wherein the active agent is the Fc fragment of the immunoglobulin molecule.

9. The isolated polynucleotide according to claim 6, wherein the conjugate comprises NKp30 covalently attached to the Fc fragment of an Ig molecule.

10. The isolated polynucleotide according to claim 6, encoding the polypeptide sequence of SEQ ID NO:4.

11. The isolated polynucleotide according to claim 6, comprising SEQ ID NO:11 or fragments thereof.
12. A vector comprising the polynucleotide of any one of claims 6 to 11.
13. The vector according to claim 12, further comprising a regulatory element operably linked to said polynucleotide, the regulatory element is selected from the group consisting of: promoter, initiation codon, stop codon, polyadenylation signal, enhancer and selection marker.
14. The vector according to claim 12, wherein the vector is a plasmid or a virus.
15. The vector according to claim 14, wherein the vector is a virus selected from the group consisting of: adenoviruses, retroviruses and lentiviruses.
16. A host cell comprising the vector of any one of claims 12 to 15.
17. A host cell capable of expressing the polypeptide conjugate any one of claims 1 to 5.
18. The host cell according to any one of claims 16-17, wherein the cell is eukaryotic or prokaryotic.
19. A pharmaceutical composition comprising as an active ingredient a polypeptide conjugate comprising:
 - (a) a target recognition segment comprising an NCR or an active fragment thereof, the NCR selected from the group consisting of: NKp30, or a functional fragment thereof, that binds to a cellular ligand expressed on the surface of a target tumor cell; and
 - (b) a second segment comprising an active agent that promotes the lysis of the target tumor cell; and
 - (c) a pharmaceutically acceptable carrier, stabilizer or diluent.
20. The pharmaceutical composition according to claim 19, wherein the active agent is selected from the group consisting of a cytotoxic agent, an immunoglobulin (Ig) molecule, and a fragment thereof.
21. The pharmaceutical composition according to claim 20, wherein the active agent is the Fc fragment of the immunoglobulin molecule.
22. The pharmaceutical composition according to claim 19, wherein the conjugate comprises NKp30 covalently attached to the Fc fragment of an Ig molecule.
23. The pharmaceutical composition according to claim 22, wherein the conjugate comprises the amino acid sequence as set forth in SEQ ID NO:4.

24. A method for treating a neoplastic disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a conjugate comprising:
- 5 (a) a target recognition segment comprising a Natural Killer cell receptor (NCR) or an active fragment thereof, the NCR is selected from the group consisting of: NKp46, NKp44, NKp30 or a functional fragment thereof that binds to a cellular ligand expressed on the surface of a target tumor cell; and
- (b) a second segment comprising an active agent, the active agent capable of exerting a cytotoxic effect on said target cell,
- 10 the conjugate being capable of eliminating or inhibiting the growth of the tumor cells associated with the disease, thereby treating the disease.
25. The method according to claim 24, wherein the conjugate is according to any one of claims 1-5.
26. The method according to claim 25, wherein the malignant disease is any
- 15 neoplastic disease is associated with a solid tumor or a non-solid tumor.
27. The method according to any one of claims 24 to 26, wherein the active agent is selected from the group consisting of: chemotherapeutic agents, radioisotopes, cytotoxins.
28. A method of inhibiting the growth of a tumor in a subject in need thereof
- 20 comprising administering to the subject a therapeutically effective amount of a polypeptide conjugate comprising:
- (a) a target recognition segment comprising an NCR or an active fragment thereof, wherein said NCR is selected from the group consisting of: NKp46, NKp44, NKp30 or a functional fragment thereof that binds to a
- 25 cellular ligand expressed on the surface of a target tumor cell; and
- (b) an active segment comprising an active substance that promotes the lysis of the target tumor cell, thereby inhibiting the growth of the tumor in said subject.
29. The method according to claim 28, wherein the conjugate is according to any
- 30 one of claims 1-5.
30. The method according to claim 29, wherein the tumor is a solid tumor or a non-solid tumor.

31. The method according to any one of claims 28 to 30, wherein the active agent is selected from the group consisting of: chemotherapeutic agents, radioisotopes, cytotoxins.
- 5 32. The method according to claim 30, wherein the solid tumor is selected from the group consisting of: carcinoma, squamous cell carcinomas, adenocarcinomas, small cell carcinomas, melanomas, gliomas and neuroblastomas.
33. The method according to claim 30, wherein the non-solid tumor is selected from the group consisting of: B cell Lymphoma, T cell Lymphoma and Leukemia.
- 10 34. The method according to claim 31, wherein the cytotoxin is a plant-, a fungus- or a bacteria-derived toxin.
35. The method according to any one of claims 24 to 34, wherein the subject is a human subject.
36. A method of delivering a cytotoxic substance to a target tumor cell in a subject comprising administering to the subject a polypeptide conjugate comprising:
- 15 a. a target recognition segment comprising an NCR or an active fragment thereof, the wherein said NCR is selected from the group consisting of: NKp46, NKp44, NKp30 or a functional fragment thereof that binds to a cellular ligand expressed on the surface of a target tumor cell; and
- 20 b. an active segment comprising the cytotoxic substance, wherein the binding of the conjugate to the cellular ligand promotes the internalization of said conjugate within said target tumor cell, thereby delivering said cytotoxic substance to said target tumor cell.
37. The method according to claim 36, wherein the conjugate is according to any one of claims 1-5.
- 25 38. The method according to any one of claims 36-37, wherein the tumor is a solid tumor or a non-solid tumor.
39. The method according to any one of claims 36 to 38, wherein the cytotoxic substance is selected from the group consisting of: chemotherapeutic agents, radioisotopes, cytotoxins.
- 30 40. The method according to claim 38, wherein the solid tumor is selected from the group consisting of: carcinoma, squamous cell carcinomas, adenocarcinomas, small cell carcinomas, melanomas, gliomas and neuroblastomas.
41. The method according to claim 38, wherein the non-solid tumor is selected from the group consisting of: B cell Lymphoma, T cell Lymphoma and Leukemia.

42. The method according to claim 39, wherein the cytotoxin is a plant-, a fungus- or a bacteria-derived toxin.
43. The method according to any one of claims 24, 28 or 36 wherein the conjugate is a polypeptide having the sequence set forth in SEQ ID NOS: 1-3.
- 5 44. The method according to any one of claims 24, 28 or 36 wherein the conjugate is a polypeptide having the sequence set forth in SEQ ID NOS: 5-7.

1/9




Figure 1

2/9





Figure 2

3/9

Figure 3



4/9




Figure 5




Figure 6




Figure 7




Figure 8





Figure 9

Pancreatic
cancer-acinar



SEQUENCE LISTING

<110> NATSPEARS LTD.

<120> NK CELL RECEPTOR CONJUGATES FOR TREATING MALIGNANCIES

<130> NAP002-PCT

<150> US 60/431,728

<151> 2002-12-09

<160> 14

<170> PatentIn version 3.1

<210> 1

<211> 488

<212> PRT

<213> Homo sapiens

<400> 1

Met Ser Ser Thr Leu Pro Ala Leu Leu Cys Val Gly Leu Cys Leu Ser
 1 5 10 15

Gln Arg Ile Ser Ala Gln Gln Gln Thr Leu Pro Lys Pro Phe Ile Trp
 20 25 30

Ala Glu Pro His Phe Met Val Pro Lys Glu Lys Gln Val Thr Ile Cys
 35 40 45

Cys Gln Gly Asn Tyr Gly Ala Val Glu Tyr Gln Leu His Phe Glu Gly
 50 55 60

Ser Leu Phe Ala Val Asp Arg Pro Lys Pro Pro Glu Arg Ile Asn Lys
 65 70 75 80

Val Lys Phe Tyr Ile Pro Asp Met Asn Ser Arg Met Ala Gly Gln Tyr
 85 90 95

Ser Cys Ile Tyr Arg Val Gly Glu Leu Trp Ser Glu Pro Ser Asn Leu
 100 105 110

Leu Asp Leu Val Val Thr Glu Met Tyr Asp Thr Pro Thr Leu Ser Val
 115 120 125

His Pro Gly Pro Glu Val Ile Ser Gly Glu Lys Val Thr Phe Tyr Cys
 130 135 140

Arg Leu Asp Thr Ala Thr Ser Met Phe Leu Leu Leu Lys Glu Gly Arg
 145 150 155 160

Ser Ser His Val Gln Arg Gly Tyr Gly Lys Val Gln Ala Glu Phe Pro
 165 170 175

Leu Gly Pro Val Thr Thr Ala His Arg Gly Thr Tyr Arg Cys Phe Gly
 180 185 190

Ser Tyr Asn Asn His Ala Trp Ser Phe Pro Ser Glu Pro Val Lys Leu
 195 200 205

Leu Val Thr Gly Asp Ile Glu Asn Thr Ser Leu Ala Pro Glu Asp Pro
 210 215 220
 Thr Phe Pro Ala Asp Thr Trp Gly Thr Tyr Leu Leu Thr Thr Glu Thr
 225 230 235 240
 Gly Leu Gln Lys Asp His Ala Leu Trp Asp His Thr Ala Gln Asp Pro
 245 250 255
 Glu Pro Lys Ser Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala
 260 265 270
 Pro Glu Phe Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro
 275 280 285
 Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val
 290 295 300
 Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val
 305 310 315 320
 Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln
 325 330 335
 Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln
 340 345 350
 Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala
 355 360 365
 Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro
 370 375 380
 Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr
 385 390 395 400
 Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser
 405 410 415
 Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr
 420 425 430
 Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr
 435 440 445
 Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe
 450 455 460
 Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys
 465 470 475 480
 Ser Leu Ser Leu Ser Pro Gly Lys
 485

<210> 2
 <211> 364
 <212> PRT
 <213> Homo sapiens

<400> 2

```

Met Gly Met Pro Met Gly Ser Leu Gln Pro Leu Ala Thr Leu Tyr Leu
1          5          10          15

Leu Gly Met Leu Val Ala Ser Cys Leu Gly Arg Leu Arg Val Pro Gln
20          25          30

Gln Gln Thr Leu Pro Lys Pro Phe Ile Trp Ala Glu Pro His Phe Met
35          40          45

Val Pro Lys Glu Lys Gln Val Thr Ile Cys Cys Gln Gly Asn Tyr Gly
50          55          60

Ala Val Glu Tyr Gln Leu His Phe Glu Gly Ser Leu Phe Ala Val Asp
65          70          75          80

Arg Pro Lys Pro Pro Glu Arg Ile Asn Lys Val Lys Phe Tyr Ile Pro
85          90          95

Asp Met Asn Ser Arg Met Ala Gly Gln Tyr Ser Cys Ile Tyr Arg Val
100         105         110

Gly Glu Leu Trp Ser Glu Pro Ser Asn Leu Leu Asp Leu Val Val Thr
115         120         125

Glu Met Asp Pro Glu Pro Lys Ser Ser Asp Lys Thr His Thr Cys Pro
130         135         140

Pro Cys Pro Ala Pro Glu Phe Glu Gly Ala Pro Ser Val Phe Leu Phe
145         150         155         160

Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val
165         170         175

Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe
180         185         190

Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro
195         200         205

Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr
210         215         220

Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val
225         230         235         240

Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala
245         250         255

```

Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg
260 265 270

Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly
275 280 285

Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro
290 295 300

Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser
305 310 315 320

Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln
325 330 335

Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His
340 345 350

Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
355 360

<210> 3
<211> 393
<212> PRT
<213> Homo sapiens

<400> 3

Met Gly Met Pro Met Gly Ser Leu Gln Pro Leu Ala Thr Leu Tyr Leu
1 5 10 15

Leu Gly Met Leu Val Ala Ser Cys Leu Gly Arg Leu Arg Val Pro Tyr
20 25 30

Asp Thr Pro Thr Leu Ser Val His Pro Gly Pro Glu Val Ile Ser Gly
35 40 45

Glu Lys Val Thr Phe Tyr Cys Arg Leu Asp Thr Ala Thr Ser Met Phe
50 55 60

Leu Leu Leu Lys Glu Gly Arg Ser Ser His Val Gln Arg Gly Tyr Gly
65 70 75 80

Lys Val Gln Ala Glu Phe Pro Leu Gly Pro Val Thr Thr Ala His Arg
85 90 95

Gly Thr Tyr Arg Cys Phe Gly Ser Tyr Asn Asn His Ala Trp Ser Phe
100 105 110

Pro Ser Glu Pro Val Lys Leu Leu Val Thr Gly Asp Ile Glu Asn Thr
115 120 125

Ser Leu Ala Pro Glu Asp Pro Thr Phe Pro Asp Thr Trp Gly Thr Tyr
130 135 140

Leu 145 Leu Thr Thr Glu 150 Thr Gly Leu Gln Lys Asp 155 His Ala Leu Trp Asp 160
 Pro Glu Pro Lys 165 Ser Ser Asp Lys Thr His 170 Thr Cys Pro Pro Cys 175 Pro
 Ala Pro Glu Phe 180 Glu Gly Ala Pro Ser 185 Val Phe Leu Phe Pro 190 Pro Lys
 Pro Lys Asp 195 Thr Leu Met Ile Ser 200 Arg Thr Pro Glu Val 205 Thr Cys Val
 Val 210 Val Asp Val Ser His Glu 215 Asp Pro Glu Val Lys 220 Phe Asn Trp Tyr
 Val 225 Asp Gly Val Glu Val 230 His Asn Ala Lys Thr 235 Lys Pro Arg Glu Glu 240
 Gln Tyr Asn Ser Thr 245 Tyr Arg Val Val Ser 250 Val Leu Thr Val Leu 255 His
 Gln Asp Trp Leu 260 Asn Gly Lys Glu Tyr 265 Lys Cys Lys Val Ser 270 Asn Lys
 Ala Leu Pro 275 Ala Pro Ile Glu Lys 280 Thr Ile Ser Lys Ala 285 Lys Gly Gln
 Pro Arg Glu 290 Pro Gln Val Tyr 295 Thr Leu Pro Pro Ser 300 Arg Asp Glu Leu
 Thr 305 Lys Asn Gln Val Ser 310 Leu Thr Cys Leu Val 315 Lys Gly Phe Tyr Pro 320
 Ser Asp Ile Ala Val 325 Glu Trp Glu Ser Asn 330 Gly Gln Pro Glu Asn 335 Asn
 Tyr Lys Thr Thr 340 Pro Pro Val Leu Asp 345 Ser Asp Gly Ser Phe 350 Phe Leu
 Tyr Ser Lys 355 Leu Thr Val Asp Lys 360 Ser Arg Trp Gln Gln 365 Gly Asn Val
 Phe Ser 370 Cys Ser Val Met His 375 Glu Ala Leu His Asn 380 His Tyr Thr Gln
 Lys 385 Ser Leu Ser Leu Ser 390 Pro Gly Lys

<210> 4
 <211> 382
 <212> PRT
 <213> Homo sapiens

<400> 4

Met Gly Met Pro Met Gly Ser Leu Gln Pro Leu Ala Thr Leu Tyr Leu

Page 6

290

295

300

Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly
 305 310 315 320

Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp
 325 330 335

Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp
 340 345 350

Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His
 355 360 365

Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
 370 375 380

<210> 5
 <211> 434
 <212> PRT
 <213> Homo sapiens

<400> 5

Met Gly Met Pro Met Gly Ser Leu Gln Pro Leu Ala Thr Leu Tyr Leu
 1 5 10 15

Leu Gly Met Leu Val Ala Ser Cys Leu Gly Arg Leu Arg Val Pro Gln
 20 25 30

Ser Lys Ala Gln Val Leu Gln Ser Val Ala Gly Gln Thr Leu Thr Val
 35 40 45

Arg Cys Gln Tyr Pro Pro Thr Gly Ser Leu Tyr Glu Lys Lys Gly Trp
 50 55 60

Cys Lys Glu Ala Ser Ala Leu Val Cys Ile Arg Leu Val Thr Ser Ser
 65 70 75 80

Lys Pro Arg Thr Val Ala Trp Thr Ser Arg Phe Thr Ile Trp Asp Asp
 85 90 95

Pro Asp Ala Gly Phe Phe Thr Val Thr Met Thr Asp Leu Arg Glu Glu
 100 105 110

Asp Ser Gly His Tyr Trp Cys Arg Ile Tyr Arg Pro Ser Asp Asn Ser
 115 120 125

Val Ser Lys Ser Val Arg Phe Tyr Leu Val Val Ser Pro Ala Ser Ala
 130 135 140

Ser Thr Gln Thr Ser Trp Thr Pro Arg Asp Leu Val Ser Ser Gln Thr
 145 150 155 160

Gln Thr Gln Ser Cys Val Pro Pro Thr Ala Gly Ala Arg Gln Ala Pro
 165 170 175

Glu Ser Pro Ser Thr Ile Pro Val Pro Ser Gln Pro Gln Asn Ser Thr
 180 185 190
 Leu Arg Pro Gly Pro Ala Ala Pro Asp Pro Glu Pro Lys Ser Ser Asp
 195 200 205
 Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Phe Glu Gly Ala
 210 215 220
 Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
 225 230 235 240
 Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu
 245 250 255
 Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His
 260 265 270
 Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg
 275 280 285
 Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
 290 295 300
 Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu
 305 310 315 320
 Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr
 325 330 335
 Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu
 340 345 350
 Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
 355 360 365
 Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val
 370 375 380
 Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp
 385 390 395 400
 Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His
 405 410 415
 Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro
 420 425 430
 Gly Lys

<210> 6
 <211> 326

<212> PRT
 <213> Homo sapiens

<400> 6

```

Met Gly Met Pro Met Gly Ser Leu Gln Pro Leu Ala Thr Leu Tyr Leu
1      5      10
Leu Gly Met Leu Val Ala Ser Cys Leu Gly Arg Leu Arg Val Pro Ser
20     25     30
Pro Ala Ser Ala Ser Thr Gln Thr Ser Trp Thr Pro Arg Asp Leu Val
35     40     45
Ser Ser Gln Thr Gln Thr Gln Ser Cys Val Pro Pro Thr Ala Gly Ala
50     55     60
Arg Gln Ala Pro Glu Ser Pro Ser Thr Ile Pro Val Pro Ser Gln Pro
65     70     75     80
Gln Asn Ser Thr Leu Arg Pro Gly Pro Ala Ala Pro Asp Pro Glu Pro
85     90     95
Lys Ser Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu
100    105    110
Phe Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp
115    120    125
Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
130    135    140
Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly
145    150    155    160
Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn
165    170    175
Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp
180    185    190
Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro
195    200    205
Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu
210    215    220
Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn
225    230    235    240
Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
245    250    255
Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr
260    265    270

```

Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys
275 280 285

Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys
290 295 300

Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
305 310 315 320

Ser Leu Ser Pro Gly Lys
325

<210> 7
<211> 376
<212> PRT
<213> Homo sapiens

<400> 7

Met Gly Met Pro Met Gly Ser Phe Gln Pro Leu Ala Thr Leu Tyr Leu
1 5 10 15

Leu Gly Met Leu Val Ala Ser Cys Leu Gly Arg Leu Arg Val Pro Gln
20 25 30

Ser Lys Ala Gln Val Leu Gln Ser Val Ala Gly Gln Thr Leu Thr Val
35 40 45

Arg Cys Gln Tyr Pro Pro Thr Gly Ser Leu Tyr Glu Lys Lys Gly Trp
50 55 60

Cys Lys Glu Ala Ser Ala Leu Val Cys Ile Arg Leu Val Thr Ser Ser
65 70 75 80

Lys Pro Arg Thr Val Ala Trp Thr Ser Arg Phe Thr Ile Trp Asp Asp
85 90 95

Pro Asp Ala Gly Phe Phe Thr Val Thr Met Thr Asp Leu Arg Glu Glu
100 105 110

Asp Ser Gly His Tyr Trp Cys Arg Ile Tyr Arg Pro Ser Asp Asn Ser
115 120 125

Val Ser Lys Ser Val Arg Phe Tyr Leu Val Val Ser Pro Ala Asp Pro
130 135 140

Glu Pro Lys Ser Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala
145 150 155 160

Pro Glu Phe Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro
165 170 175

Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val
180 185 190

Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val
 195 200 205
 Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln
 210 215 220
 Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln
 225 230 235 240
 Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala
 245 250 255
 Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro
 260 265 270
 Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr
 275 280 285
 Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser
 290 295 300
 Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr
 305 310 315 320
 Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr
 325 330 335
 Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe
 340 345 350
 Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys
 355 360 365
 Ser Leu Ser Leu Ser Pro Gly Lys
 370 375

<210> 8
 <211> 1506
 <212> DNA
 <213> Homo sapiens

<400> 8
 tccccactgc tcagcactta ggccggcaga atctgagcga tgtcttccac actccctgcc 60
 ctgctctgcg tcgggctgtg tctgagtcag aggatcagcg cccagcagca gactctccca 120
 aaaccgttca tctgggcccga gcccatttc atggttccaa aggaaaagca agtgaccatc 180
 tgttgccagg gaaattatgg ggctgttgaa taccagctgc actttgaagg aagccttttt 240
 gccgtggaca gaccaaacc ccctgagcgg attaacaaag tcaaattcta catcccggac 300
 atgaactccc gcatggcagg gcaatacagc tgcattctatc gggttgggga gctctggtca 360
 gagcccagca acttgctgga tctggtggtta acagaaatgt atgacacacc caccctctcg 420
 gttcatcctg gacccgaagt gatctcggga gagaagggtga ccttctactg ccgtctagac 480
 actgcaacaa gcatgttctt actgctcaag gaggggaagat ccagccacgt acagcgcgga 540

tacgggaagg	tccaggcgga	gttccccctg	ggccctgtga	ccacagccca	ccgagggaca	600
taccgatgtt	ttggctccta	taacaaccat	gcctgggtctt	tccccagtga	gccagtgaag	660
ctcctgggtca	caggcgacat	tgagaacacc	agccttgacac	ctgaagaccc	cacctttcct	720
gcagacactt	ggggcaccta	ccttttaacc	acagagacgg	gactccagaa	agaccatgcc	780
ctctgggatc	acactgcca	ggatccggag	cccaaattctt	ctgacaaaac	tcacacatgc	840
ccaccgtgcc	cagcacctga	attcgagggg	gcaccgtcag	tcttcctctt	cccccaaaa	900
ccaaggaca	ccctcatgat	ctcccgacc	cctgaggtca	catgcgtggg	ggtggacgtg	960
agccacgaag	accctgaggt	caagttcaac	tggtacgtgg	acggcgtgga	ggtgcataat	1020
gccaagacaa	agccgcggga	ggagcagtag	aacagcacgt	accgtgtggg	cagcgtcctc	1080
accgtcctgc	accaggactg	gctgaatggc	aaggagtaca	agtgcaagg	ctccaacaaa	1140
gccctcccag	cccccatcga	gaaaaccatc	tccaaagcca	aagggcagcc	ccgagagcca	1200
caggtgtaca	ccctgcccc	atcccgggat	gagctgacca	agaaccagg	cagcctgacc	1260
tgcttgggtca	aaggcttcta	tcccagcgac	atcgccgtgg	agtgggagag	caatgggcag	1320
ccggagaaca	actacaagac	cacgcctccc	gtgctggact	ccgacggctc	cttcttcctc	1380
tacagcaagc	tcaccgtgga	caagagcagg	tggcagcagg	ggaacgtctt	ctcatgctcc	1440
gtgatgcatg	aggctctgca	caaccactac	acgcagaaga	gcctctccct	gtctccgggt	1500
aaatga						1506

<210> 9
 <211> 1110
 <212> DNA
 <213> Homo sapiens

<400> 9						
aagcttgccg	ccaccatggg	aatgcccattg	gggtctctgc	aaccgctggc	caccttgtac	60
ctgctgggga	tgctggctgc	ttcctgcctc	ggacggctca	gggtaccca	gcagcagact	120
ctcccaaac	cgttcatctg	ggccgagccc	catttcatgg	ttccaaagga	aaagcaagtg	180
accatctgtt	gccagggaaa	ttatggggct	gttgaatacc	agctgcactt	tgaagggaagc	240
ctttttgccg	tggacagacc	aaaaccccct	gagcggatta	acaagtcaa	attctacatc	300
ccggacatga	actcccgcac	ggcagggcaa	tacagctgca	tctatcgggt	tggggagctc	360
tggtcagagc	ccagcaactt	gctggatctg	gtggtaacag	aaatggatcc	ggagcccaaa	420
tcttctgaca	aaactcacac	atgcccaccg	tgcccagcac	ctgaattcga	gggtgcaccg	480
tcagtcttcc	tcttcccccc	aaaacccaag	gacaccctca	tgatctcccg	gacccctgag	540
gtcacatgcg	tgggtggtgga	cgtgagccac	gaagaccctg	aggtcaagtt	caactgggtac	600
gtggacggcg	tggaggtgca	taatgccaa	acaaagccgc	gggaggagca	gtacaacagc	660
acgtaccgtg	tggtcagcgt	cctcaccgtc	ctgcaccagg	actggctgaa	tggcaaggag	720
tacaagtgca	aggctctcaa	caaagccctc	ccagcccca	tcgagaaaac	catctccaaa	780
gccaagggc	agccccgaga	gccacaggtg	tacaccctgc	ccccatcccg	ggatgagctg	840
accaagaacc	aggtcagcct	gacctgcctg	gtcaaaggct	tctatcccag	cgacatcgcc	900
gtggagtggg	agagcaatgg	gcagccggag	aacaactaca	agaccacgcc	tcccgtgctg	960

gactccgacg gctccttctt cctctacagc aagctcaccg tggacaagag caggtggcag 1020
 caggggaacg tcttctcatg ctccgtgatg catgaggctc tgcacaacca ctacacgcag 1080
 aagagcctct ccctgtctcc gggtaaata 1110

<210> 10
 <211> 1197
 <212> DNA
 <213> Homo sapiens

<400> 10
 aagcttgccg ccaccatggg aatgcccacg gggctctctg aaccgctggc caccttgtac 60
 ctgctgggga tgctggctgc ttcctgcctc ggacggctca gggtagccta tgacacaccc 120
 accctctcgg ttcctcctgg acccgagggt atctcgggag agaagggtgac cttctactgc 180
 cgtctagaca ctgcaacaag catgttctta ctgctcaagg aggggaagatc cagccacgta 240
 cagcgcggat acgggaaggt ccaggcggag tccccctgg gccctgtgac cacagccac 300
 cgagggacat accgatgttt tggctcctat aacaaccatg cctgggtcttt cccagtgag 360
 ccagtgaagc tcctggctac aggcgacatt gagaacacca gccttgacc tgaagacccc 420
 acctttcctg acacttgggg cacctacctt ttaaccacag agacgggact ccagaaagac 480
 catgccctct gggatccgga gcccacatct tctgacaaa ctcacacatg cccaccgtgc 540
 ccagcacctg aattcgaggg tgcaccgtca gtcttctct tcccccaaa acccaaggac 600
 accctcatga tctcccgga ccctgagggt acatgcgtgg tggtaggacgt gagccacgaa 660
 gaccctgagg tcaagttcaa ctggtacgtg gacggcgtgg aggtgcataa tgccaagaca 720
 aagccgcggg aggagcagta caacagcacg taccgtgtgg tcagcgtcct caccgtcctg 780
 caccaggact ggctgaatgg caaggagtac aagtgcagg tctccaacaa agccctccca 840
 gcccccatcg agaaaacat ctccaaagcc aaagggcagc cccgagagcc acagggtgtac 900
 accctgcccc catcccgga tgagctgacc aagaaccagg tcagcctgac ctgcctgggtc 960
 aaaggcttct atcccagcga catcgccgtg gagggggaga gcaatgggca gccggagaac 1020
 aactacaaga ccacgcctcc cgtgctggac tccgacggct ctttcttct ctacagcaag 1080
 ctcaccgtgg acaagagcag gtggcagcag gggaacgtct tctcatgctc cgtgatgcat 1140
 gaggctctgc acaaccacta cacgcagaag agcctctccc tgtctccggg taaatga 1197

<210> 11
 <211> 1164
 <212> DNA
 <213> Homo sapiens

<400> 11
 aagcttgccg ccaccatggg aatgcccacg gggctctctg aaccgctggc caccttgtac 60
 ctgctgggga tgctggctgc ttcctgcctc ggacggctca gggtagccta ctgggtgtcc 120
 cagccccttg agattcgtac cctggaaggg tcttctgcct tctgcccctg ctcttcaat 180
 gccagccaag ggagactggc cattgggtcc gtcacgtggg tccgagatga ggtggttcca 240
 ggggaaggagg tgaggaatgg aacccagag ttcaggggccc gcctggcccc attgcttct 300
 tcccgtttcc tccatgacca ccaggctgag ctgcacatcc gggacgtgcg aggcacgtac 360

tcccgtttcc	tccatgacca	ccaggctgag	ctgcacatcc	gggacgtgcg	aggccatgac	360
gccagcatct	acgtgtgcag	agtggagggtg	ctgggccttg	gtgtcgggac	agggaatggg	420
actcggctgg	tgggtggagaa	agaacatcct	cagctagggg	atccggagcc	caaatcttct	480
gacaaaactc	acacatgccc	accgtgccc	gcacctgaat	tcgagggtgc	accgtcagtc	540
ttcctcttcc	ccccaaaacc	caaggacacc	ctcatgatct	cccggacccc	tgaggtcaca	600
tgcgtgggtg	tggacgtgag	ccacgaagac	cctgagggtca	agttcaactg	gtacgtggac	660
ggcgtggagg	tgcataatgc	caagacaaag	ccgcgggagg	agcagtacaa	cagcacgtac	720
cgtgtgggtca	gcgtcctcac	cgtcctgcac	caggactggc	tgaatggcaa	ggagtacaag	780
tgcaagggtct	ccaacaaagc	cctcccagcc	cccacgaga	aaaccatctc	caaagccaaa	840
gggcagcccc	gagagccaca	ggtgtacacc	ctgcccccat	cccgggatga	gctgaccaag	900
aaccagggtca	gcctgacctg	cctgggtcaaa	ggcttctatc	ccagcgacat	cgccgtggag	960
tgggagagca	atgggcagcc	ggagaacaac	tacaagacca	cgcttcccgt	gctggactcc	1020
gacggctcct	tcttctctta	cagcaagctc	accgtggaca	agagcagggtg	gcagcagggg	1080
aacgtcttct	catgctccgt	gatgcatgag	gctctgcaca	accactacac	gcagaagagc	1140
ctctccctgt	ctccgggtaa	atga				1164

<210> 12
 <211> 1320
 <212> DNA
 <213> Homo sapiens

<400> 12						
aagcttgccg	ccaccatggg	aatgcccattg	gggtctctgc	aaccgctggc	caccttgtac	60
ctgctgggga	tgctggctgc	ttcctgcctc	ggacggctca	gggtaccca	atccaaggct	120
caggctacttc	aaagtgtggc	agggcagacg	ctaaccgtga	gatgccagta	cccgccacg	180
ggcagtctct	acgagaagaa	aggctgggtgt	aaggaggctt	cagcacttgt	gtgcatcagg	240
ttagtcacca	gctccaagcc	caggacgggtg	gcttggacct	ctcgattcac	aatctgggac	300
gaccttgatg	ctggcttctt	cactgtcacc	atgactgatc	tgagagagga	agactcagga	360
cattactgggt	gtagaatcta	ccgcccttct	gacaactctg	tctctaagtc	cgtcagattc	420
tatctgggtg	tatctccagc	ctctgcctcc	acacagacct	cctggactcc	ccgcgacctg	480
gtctcttcac	agaccagac	ccagagctgt	gtgcctccca	ctgcaggagc	cagacaagcc	540
cctgagtctc	catctaccat	ccctgtccct	tcacagccac	agaactccac	gctccgccct	600
ggccctgcag	ccccggatcc	ggagcccaaa	tcttctgaca	aaactcacac	atgcccaccg	660
tgcccagcac	ctgaattcga	gggtgcaccg	tcagtcttcc	tcttcccccc	aaaaccaag	720
gacaccctca	tgatctcccg	gaccctgag	gtcacatgcg	tgggtgggtga	cgtgagccac	780
gaagaccctg	aggtcaagtt	caactggtac	gtggacggcg	tggagggtgca	taatgccaag	840
acaagccgc	gggaggagca	gtacaacagc	acgtaccgtg	tggtcagcgt	cctcaccgtc	900
ctgcaccagg	actggctgaa	tggcaaggag	tacaagtgca	aggtctccaa	caaagccctc	960
ccagccccca	tcgagaaaac	catctccaaa	gccaaagggc	agccccgaga	gccacagggtg	1020
tacaccctgc	ccccatcccg	ggatgagctg	accaagaacc	aggtcagcct	gacctgcctg	1080

gtcaaaggct	tctatcccag	cgacatcgcc	gtggagtggg	agagcaatgg	gcagccggag	1140
aacaactaca	agaccacgcc	tcccgtgctg	gactccgacg	gctccttctt	cctctacagc	1200
aagctcaccg	tggacaagag	caggtggcag	caggggaacg	tcttctcatg	ctccgtgatg	1260
catgaggctc	tgcacaacca	ctacacgcag	aagagcctct	ccctgtctcc	gggtaaata	1320

<210> 13
 <211> 996
 <212> DNA
 <213> Homo sapiens

<400> 13						
aagcttgccg	ccaccatggg	aatgcccattg	gggtctctgc	aaccgctggc	caccttgtac	60
ctgctgggga	tgctggtcgc	ttcctgcctc	ggacggctca	gggtaccctc	tccagcctct	120
gcctccacac	agacctcctg	gactccccgc	gacctggtct	cttcacagac	ccagaccag	180
agctgtgtgc	ctcccactgc	aggagccaga	caagcccctg	agtctccatc	taccatccct	240
gtcccttcac	agccacagaa	ctccacgctc	cgccctggcc	ctgcagcccc	ggatccggag	300
cccaaattctt	ctgacaaaac	tcacacatgc	ccaccgtgcc	cagcacctga	attcgagggg	360
gcaccgtcag	tcttcctctt	ccccccaaa	ccaaggaca	ccctcatgat	ctcccggacc	420
cctgagggtca	catgctgggt	ggtggacgtg	agccacgaag	accctgaggt	caagttcaac	480
tggtacgtgg	acggcgtgga	ggtgcataat	gccaaagaca	agccgcggga	ggagcagtag	540
aacagcacgt	accgtgtgggt	cagcgtcctc	accgtcctgc	accaggactg	gctgaatggc	600
aaggagtaca	agtgaagggt	ctccaacaaa	gccctcccag	cccccatcga	gaaaaccatc	660
tccaaagcca	aagggcagcc	ccgagagcca	caggtgtaca	ccctgcccc	atcccgggat	720
gagctgacca	agaaccaggt	cagcctgacc	tgctgtgtca	aaggcttcta	tcccagcgac	780
atcgccgtgg	agtgggagag	caatgggcag	ccggagaaca	actacaagac	cacgcctccc	840
gtgctggact	ccgacggctc	cttcttcctc	tacagcaagc	tcaccgtgga	caagagcagg	900
tggcagcagg	ggaacgtctt	ctcatgctcc	gtgatgcatg	aggctctgca	caaccactac	960
acgcagaaga	gcctctccct	gtctccgggt	aaatga			996

<210> 14
 <211> 1146
 <212> DNA
 <213> Homo sapiens

<400> 14						
aagcttgccg	ccaccatggg	aatgcccattg	gggtctctgc	aaccgctggc	caccttgtac	60
ctgctgggga	tgctggtcgc	ttcctgcctc	ggacggctca	gggtaccca	atccaaggct	120
caggtacttc	aaagtgtggc	agggcagacg	ctaaccgtga	gatgccagta	cccgccacg	180
ggcagtctct	acgagaagaa	aggctggtgt	aaggaggctt	cagcacttgt	gtgcatcagg	240
ttagtacca	gctccaagcc	caggacgggtg	gcttggacct	ctcgattcac	aatctgggac	300
gaccctgatg	ctggcttctt	cactgtcacc	atgactgata	tgagagagga	agactcagga	360
cattactggg	gtagaatcta	ccgcccttct	gacaactctg	tctctaagtc	cgtcagattc	420
tatctgggtg	tatctccagc	ggatccggag	cccaaattctt	ctgacaaaac	tcacacatgc	480

ccaccgtgcc cagcacctga attcgaggggt gcaccgtcag tcttcctctt ccccccaaaa	540
cccaaggaca ccctcatgat ctcccggacc cctgaggtca catgcgtggt ggtggacgtg	600
agccacgaag accctgaggt caagttcaac tggtagctgg acggcgtgga ggtgcataat	660
gccaagacaa agccgcggga ggagcagtac aacagcacgt accgtgtggt cagcgtcctc	720
accgtcctgc accaggactg gctgaatggc aaggagtaca agtgcaaggt ctccaacaaa	780
gccctcccag ccccatcgaa gaaaaccatc tccaaagcca aagggcagcc ccgagagcca	840
caggtgtaca ccctgcccc atcccgggat gagctgacca agaaccaggt cagcctgacc	900
tgcttggtca aaggcttcta tcccagcgac atcgccgtgg agtgggagag caatgggcag	960
ccggagaaca actacaagac cagcctccc gtgctggact ccgacggctc cttcttcctc	1020
tacagcaagc tcaccgtgga caagagcagg tggcagcagg ggaacgtctt ctcatgctcc	1080
gtgatgcatg aggctctgca caaccactac acgcagaaga gcctctccct gtctccgggt	1140
aaatga	1146